US Pat. No. 10,653,118

COANDA EFFECT FISH PUMP

1. A Coanda effect fish pump for transporting live fish by induced flow and removing sea lice from the live fish, said pump comprisinga housing having a primary intake for primary flow, and a secondary intake for induced flow creating an interior water injection flow path terminating at a collector;
said collector chamber for intermixing said primary flow and said induced flow, and an outlet for discharge;
an orifice forming a circumferential flow gap having an irregular space between said primary intake and said collector chamber forming a flow path for said primary flow, said orifice including at least fifteen flutes each having a width and a depth define by spaced apart surface depressions formed along an end wall of the interior water injection flow path, said flutes are not all the same width and depth positioned to represent the profile of a fish with about 40% of said primary flow passing through said flutes and directing said primary flow at an acute angle to an axis defined by said induced flow;
wherein said irregular space of said orifice and said flutes form an unsymmetrical gap to adjust water flow conducive to the removal of sea lice from fish.

US Pat. No. 10,653,117

PORTABLE NIPPLE BASED ANIMAL WATERER

Chickenwaterer.com LLC, ...

1. A portable animal waterer, comprising:a bulbous manifold formed from a manifold wall, wherein the bulbous manifold is configured to hold a fluid;
a connector formed from an extension of the bulbous manifold,
wherein the bulbous manifold is connected to a portable water container using the connector,
wherein the connector enters the portable water container at a wall of the portable water container, surface-normal to the wall of the portable water container, and
wherein the bulbous manifold is supported by the portable water container;
a first valve hole disposed on the bulbous manifold in the manifold wall in a first plane tangential to the manifold wall at the first valve hole, wherein the first valve hole is configured to receive a first valve; and
a second valve hole disposed on the bulbous manifold in the manifold wall in a second plane tangential to the manifold wall at the second valve hole, opposite to the first valve hole,
wherein the second valve hole is configured to receive a second valve, and
wherein the second plane is parallel to the first plane.

US Pat. No. 10,653,116

REDUCE PULL LEASH APPARATUS AND METHODS

1. A reduced-pull leash device comprising:a first leash section that is extendible, the first leash section having a length, a first end and a second end; and
a leash having one or more mounting locations;
wherein the first end of the first leash section is configured to fixedly couple to one of the one or more mounting locations of the leash so as to define a second leash section within the leash, the second leash section having a length and a first end and a second end, the first end located where the first end of the first leash section fixedly couples to the leash at one of the one or more mounting locations;
wherein the length of the second leash section is longer than the length of the first leash section while the first leash section is unextended;
wherein the second end of the first leash section is configured to couple to a dog harness at a location on top of a dog;
wherein the second end of the second leash section is configured to couple to a dog harness at a front location of the dog;
wherein the length of the first leash section and the length of the second leash section are configured so that the first leash section extends when a dog pulls on the leash until the second leash section becomes taut; and
wherein once the second leash section becomes taut, a lateral force is generated at the front location of the dog by the second leash section so as to pull the dog laterally.

US Pat. No. 10,653,115

SUSPENDED ZIPLINE DOG TOY FOR SOLO PLAY

1. An apparatus, comprising:a dog toy;
a first support;
a second support, wherein the first support and the second support are separated by a distance;
a tightening mechanism attached to the second support;
an inelastic line looped around the first support at a first end of the inelastic line, and attached to the tightening mechanism at a second end to the second support, wherein:
the inelastic line is elevated above the ground; and
the inelastic line is an anchored line that remains substantially taut when attached to the first support and the second support to provide a line for the dog toy to slide along;
a slider comprising a tube fit around the inelastic line, wherein the inelastic line is configured to provide a substantially taut support line for the slider to slide between the first support and the second support;
a first stretchable and self-retracting line attached at a first fixed end to a loop of the inelastic line looped around the first support and attached at a first sliding end to the slider;
a second stretchable and self-retracting line attached at a second fixed end to the tightening mechanism and attached at a second sliding end to the slider, wherein:
the first stretchable and self-retracting line and the second stretchable and self-retracting line are suspended above the ground;
the first stretchable and self-retracting line or the second stretchable and self-retracting line is configured to temporarily expand or contract in length along a horizontal plane and then return to an original position;
the first stretchable and self-retracting line or the second stretchable and self-retracting line is configured to:
expand or contract along the horizontal plane as the slider is pulled toward the first support or the second support; and
center the slider to approximately a center location along the horizontal plane of the inelastic line as the slider is released; and
the dog toy affixed to the first stretchable and self-retracting line, the second stretchable and self-retracting line, and the slider to suspend the dog toy above the ground and below the first stretchable and self-retracting line, the second stretchable and self-retracting line, and the inelastic line.

US Pat. No. 10,653,114

RECONFIGURABLE ANIMAL TRANING APPARATUS AND SYSTEM

E-Collar Technologies, In...

1. An animal training system comprising an animal training apparatus worn on an animal to deliver stimulation to the animal and a remote controller possessed by a user to control the animal training apparatus, the remote controller and the animal training apparatus configured to communicate with each other via wireless communication,the animal training apparatus comprising:
a stimulation generator/stimulator module to generate the stimulation and deliver the stimulation to the animal;
a wireless communication module to receive a signal from the remote controller; and
a microprocessor configured to control the stimulation generator/stimulator module to deliver the stimulation to the animal based on the signal received by the wireless communication module, and
the remote controller comprising:
a user input means to select a particular stimulation mode from a plurality of stimulation modes differing in type, duration, and/or intensity of the stimulation to be delivered by the animal training apparatus or a particular function from a plurality of functions provided by the animal training system and input an execution command of the selected stimulation mode or function;
a wireless communication module to transmit signals representing the stimulation mode or function selected by the user input means to the animal training apparatus; and
a microprocessor to process the signals and control the wireless communication module,
wherein at least a portion of the user input means or functions is reconfigurable by the user,
wherein the user input means of the remote controller includes a plurality of buttons each assigned corresponding to a particular stimulation mode or a particular function, and
wherein a corresponding relationship between the plurality of buttons and the plurality of stimulation modes or functions are reconfigurable by the user.

US Pat. No. 10,653,113

RESTRAINT ASSEMBLY FOR AN ANIMAL

K-9 MD INCORPORATED, Tor...

1. A restraint assembly for an animal comprising:a front anchor member, the front anchor member configured to be secured to an animal through an interaction with at least one of a neck, a first front leg, and second front leg thereof;
a rear anchor member, the rear anchor member configured to be secured to an animal through interaction with at least one of a tail, a first rear leg, and a second rear leg thereof; and
a coupling assembly coupling the front anchor member to the rear anchor member in releasable engagement, to limit articulation of a body of the animal, sufficient to substantially preclude a head of the animal to rotate and reach portions of behind the head with a mouth of the animal;
wherein:
the front anchor member includes a first side attachment region on a first side of the front anchor member, a second side attachment region on a second side if the front anchor member and a top attachment region on a top of the front anchor member,
the rear anchor member includes a first side attachment region on a first side of the rear anchor member, a second side attachment region on a second side of the rear anchor member and a top attachment region on a top of the rear anchor member; and
the coupling assembly further includes at least a first strap assembly coupling the first side attachment region of the front anchor member to the first side attachment region of the rear anchor member, and a second side strap assembly coupling the second side attachment region of the front anchor member to the second side attachment region of the rear anchor member.

US Pat. No. 10,653,112

INFORMATION PROCESSING SYSTEM AND METHOD FOR MANAGING GROUPS OF INDIVIDUALS

SONY CORPORATION, Tokyo ...

1. An information processing apparatus, comprising:a processor configured to:
extract a plurality of group constituent individuals that belong to a group from a plurality of individuals based on individual information of each individual of the plurality of individuals;
determine that an individual of the plurality of group constituent individuals is an attention-needing individual in an attention-needing state, based on individual velocity vector of each group constituent individual of the plurality of group constituent individuals and a group velocity vector of the group; and
control a display screen to display;
a shape of a region occupied by the group as a group indication in a map image based on a distribution of position information items of a plurality of peripheral constituent individuals, wherein the plurality of peripheral constituent individuals form a periphery of the group among the plurality of group constituent individuals; and
the attention-needing individual as an attention-needing-individual indication in the map image.

US Pat. No. 10,653,111

WILDLIFE BAITING ASSEMBLY

1. A wildlife baiting assembly comprising:a cylinder having a top and a bottom, said top and said bottom being open, said cylinder being tapered proximate to said bottom defining a cone and a reservoir, said cylinder being substantially circular shaped when viewed longitudinally;
a base coupled to and extending from said cylinder, said base being coupled to said cylinder proximate to a lower end of said reservoir,
a base coupled to and extending from said cylinder, said base being tripoidal, said base comprising
a set of sockets coupled to said cylinder, and
a set of legs positioned singly in said sockets such that said legs are coupled to and extend angularly from said cylinder;
a lid complementary to said top, said lid being reversibly couplable to said cylinder to close said top;
a coupler coupled to a perimeter of said lid;
a pole coupled to and extending from a respective said socket to said coupler, said pole being rotationally coupled to said coupler;
a rod coupled to said lid and extending perpendicularly from said perimeter of said lid, said rod being opposingly positioned on said perimeter relative to said coupler;
a tube coupled to said cylinder, said tube being complementary to said rod, wherein said coupler is positioned on said lid such that said coupler is positioned to couple to said pole to rotationally couple said lid to said pole, wherein said tube is positioned on said cylinder such that said tube is positioned for inserting said rod to couple said lid to said cylinder to close said top;
a battery coupled to said cylinder, said battery being rechargeable;
a plurality of solar cells operationally coupled to said battery such that said solar cells are positioned for recharging said battery;
a disbursing unit coupled to said cylinder and positioned below said cone, said disbursing unit being operationally coupled to said battery;
a plurality of sensors coupled to said cylinder, said sensors being operationally coupled to said battery, said sensors being configured for detecting motion proximate to said cylinder; and
wherein said top is positioned on said cylinder such that said top is configured for inserting feed into said reservoir, wherein said base is positioned on said cylinder such that said base is positioned to elevate said cylinder above a surface upon which said base is disposed, wherein said disbursing unit is positioned on said cylinder such that said disbursing unit is configured for broadcasting the feed dropping from said cylinder to an area proximate to said base at specified intervals and for specified lengths of time, and wherein said sensors are configured for detecting motion proximate to said base and said cylinder.

US Pat. No. 10,653,110

CONTROL UNIT FOR GAME OR FISH FEEDER

1. A control unit for a game or fish feeder comprising a spreader, wherein the control unit is arranged for mounting on or in connection to the feeder, said control unit comprising:a controller circuitry controlling the powering of a drive unit of said feeder for controlled output of feed from the feeder;
a wireless transmitter arranged to communicate over a wireless network with a remote unit;
a sensor for measuring a parameter of the feeder; and
a processor determining whether a measured parameter value provided by said sensor fulfills a predetermined condition in order to detect an action-requiring state of the feeder,
wherein, in response to a detected action-requiring state, the wireless transmitter is triggered to send a notification to said remote unit;
wherein the control unit is formed as a self-contained box, and wherein the self-contained box comprises an input for connection to a battery, and an output for connection to said drive unit of the feeder such that the control unit controllably provides power from said battery to said drive unit;
wherein said sensor comprises a power sensor for measuring the power consumption of said drive unit, and wherein said predetermined condition is a deviation from a predetermined desired value of the power consumption relating to the power consumption during normal functioning of the feeder,
wherein a lower threshold value indicates a lowest allowed power consumption and a higher threshold value indicates a highest allowed power consumption, the lower and higher threshold values being related to power consumptions for predetermined conditions that correspond to operational disturbances, and
wherein the lower threshold value is set above a power consumption for driving an empty spreader so that a condition of no feed being provided onto the spreader may be detected.

US Pat. No. 10,653,109

FARROWING SYSTEM WITH PIGLET BIRTH DETECTION AND METHOD FOR OPERATING THE SAME

JYGA CONCEPT INC., Saint...

1. A farrowing system comprising:a farrowing pen adapted to receive a sow;
a feed dispenser for dispensing feed to the sow received in the farrowing pen according to a first feeding pattern;
a birth detection sensor for detecting a birth of a piglet from the sow;
at least one heating element for providing heat to a portion of the farrowing pen;
a controller operatively connected to the birth sensor and to the feed dispenser for switching from the first feeding pattern to a second feeding pattern upon detection of the birth of the piglet, the controller being further connected to the at least one heating element for activating the at least one heating element upon the detection of the birth of the piglet,
wherein the controller is further configured for deactivating the at least one heating element during a providing of the feed and reactivating the at least one heating element after the providing of the feed to control a power consumption of the farrowing system.

US Pat. No. 10,653,108

JOINT WITH AUTOMATIC LOCKING JOINT FOR RECONFIGURABLE DEVICE AND METHOD OF MANUFACTURE

Adjustajoints LLC, Overl...

1. A joint comprising:a first receiver having at least one through hole extending entirely through the first receiver, and at least one non-through hole extending partially through the first receiver;
a second receiver having at least one other non-through hole extending partially through the second receiver;
a biasing assembly at least partially housed in at least one of the first receiver or the second receiver; and
a locking mechanism operable to drive the biasing assembly out of the at least one of the first receiver or the second receiver.

US Pat. No. 10,653,107

RECONFIGURABLE PET POTTY SYSTEM WITH AUTOMATIC LOCKING JOINT AND METHOD OF MANUFACTURE

Adjustajoints, LLC, Over...

1. A reconfigurable pet potty system comprising:a plurality of frames secured together via a plurality of joints including pivot joints, each of the plurality of frames (i) defined by a plurality of elongated frame members, and (ii) selectively pivotable with respect to another one or more of the frames,
wherein,
each of the plurality of frames define one of a plurality of interior voids,
each of the plurality of interior voids includes a sheet removably secured therein, and
each of the pivot joints includes a locking mechanism (i) having a plurality of locking points, and (ii) operable to allow pivoting of at least one of the plurality of frames between the plurality of locking points when the locking mechanism is actuated.

US Pat. No. 10,653,106

COLLAPSIBLE LITTER BOX

DOSKOCIL MANUFACTURING CO...

1. A litter box comprising:a first shell portion that is a top shell having a first connection portion, a handle, a first cavity portion and having a doorway formed therein to permit ingress and egress of an animal, a top surface of the first shell portion having a filter receptacle that receives a filter, the handle protruding from the top surface of the first shell portion such that the handle is fixedly positioned directly over the filter receptacle, the receptacle having an opening formed on the first shell underneath the top surface between the handle and the first cavity portion, the opening being directly below the handle and extending the entire width and length of the handle, the shape of the opening being substantially the same as the shape of the handle to enable the first shell portion to be injection molded with the handle integrally formed with the top surface of the first shell portion;
a second shell portion having a second connection portion and a second cavity portion, the second shell portion being a bottom shell of the litter box, the second connection portion having a support,
the first and second shell portions being movable between a first configuration and a second configuration,
in the first configuration, the second shell portion being nested within the first cavity portion and in the second configuration, the first connection portion being engaged with the support of the second shell portion such that the first shell portion is disposed on top of the second shell portion.

US Pat. No. 10,653,105

ANIMAL ENCLOSURE

CHEYL PTY LTD AS TRUSTEE ...

1. An animal enclosure comprising: a circular, partly circular or semicircular wall or fence, at least a first moveable barrier and a second moveable barrier located within the enclosure, wherein the first moveable barrier and the second moveable barrier are separately rotatable about the same vertical axis, and a rotation actuator that causes rotation of at least the first moveable barrier and the second moveable barrier, the rotation actuator being operable by an operator, the rotation actuator comprising a part or a portion located externally of the enclosure to thereby allow an operator to move at least the first moveable barrier and the second moveable barrier from a location that is external to the enclosure; wherein both the first moveable barrier and the second moveable barrier are moveable by operation of the rotation actuator.

US Pat. No. 10,653,104

LIGHTING DEVICE FOR USE IN LIGHTING OF CHEESE

SIGNIFY HOLDING B.V., Ei...

1. A method of selecting the suitability of a lighting device for use in cheese lighting, the method comprising (a) defining a normalization factor for a spectral power distribution (SPD(?)) of lighting device light of said lighting device in a wavelength range of 380-780 nm, (b) defining the lighting device suitable for use in cheese lighting when a cheese damage function value (CDFV) is equal to or below 2, wherein the cheese damage function value (CDFV) is defined as:
wherein:

wherein y(?) is the 2-degree color matching function, and
wherein DF(?)=1 for 380 nm??<410, and
wherein for 410???780:

US Pat. No. 10,653,103

ROBOTIC ARM WITH IMPROVED MOTION

TECHNOLOGIES HOLDINGS COR...

1. An apparatus comprising:a carriage coupled to a track, the carriage configured to move along the track in a lateral direction;
a platform coupled to the carriage and positioned above the carriage, the platform having a length and a width orthogonal to the length, the length greater than the width and transverse to the lateral direction when in an operational state, the platform comprising a front end and a back end, the platform configured to pivot about a fulcrum positioned beneath the platform between the platform and the carriage such that when the platform pivots, the front end and the back end move vertically in opposite directions;
an extension member movably coupled to the platform, the extension member having a front end and a back end, the extension member further having a longitudinal axis that extends from the front end of the extension member to the back end of the extension member and is parallel to the length of the platform, the extension member configured to extend away from the carriage in a first mode of operation and retract back towards the carriage in a second mode of operation; and
a spray tool member coupled to the front end of the extension member.

US Pat. No. 10,653,102

ROBOTIC ARM

Technologies Holdings Cor...

1. An apparatus comprising:a carriage coupled to a track along a bottom surface of the carriage, the carriage configured to move along the track;
a foundation coupled to a top surface of the carriage, the top surface of the carriage opposite the bottom surface of the carriage;
a pivot coupler coupled to the foundation;
a platform comprising a top surface and a bottom surface, the bottom surface of the platform opposite the top surface of the platform, the top surface of the platform having a length in a lengthwise direction and a width orthogonal to the length, the length greater than the width;
a coupler coupled to the bottom surface of the platform, the coupler configured to couple the platform to the pivot coupler such that the platform may pivot about the pivot coupler;
a linear actuator coupled to the top surface of the platform;
an extension member coupled to the linear actuator such that the linear actuator may move the extension member in the lengthwise direction along the platform and away from the carriage;
a spray tool member coupled to the extension member; and
a controller configured to cause the carriage to move along the track, the platform to pivot, and the extension member to move in the lengthwise direction to position a spray tool coupled to the spray tool member at a spray position from which the spray tool may discharge a solution to a teat of a dairy livestock.

US Pat. No. 10,653,101

VISION SYSTEM WITH TEAT IDENTIFICATION

Technologies Holdings Cor...

1. A vision system comprising:a robotic arm comprising a laser configured to scan at least a portion of a dairy livestock in a stall;
a memory configured to store teat location information comprising teat locations for a plurality of teats of the dairy livestock; and
a processor operably coupled to the laser and the memory, and configured to:
position the laser adjacent to the dairy livestock;
modify teat location information for one or more teats from the plurality of teats of the dairy livestock based on a robot position offset between a center line of the dairy livestock and a position of the robotic arm;
generate a teat position associated with an unknown teat based on the scan of the at least a portion of the dairy livestock;
identify a first teat and a second teat from among the plurality of teats of the dairy livestock based on the teat position for the unknown teat;
determine a first position distance between the teat position and a first modified teat location for the first teat of the plurality of teats;
determine a second position distance between the teat position and a second modified teat location for the second teat of the plurality of teats;
compare the first position distance and the second position distance to determine a smallest position distance from the unknown teat;
identify a teat from the plurality of teats of the dairy livestock corresponding with the smallest position distance;
associate a teat identifier for the unknown teat with the identified teat; and
store the association between the teat identifier and the teat position in the memory.

US Pat. No. 10,653,084

LETTUCE VARIETY 41-479 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A seed of lettuce variety 41-479 RZ, a sample of seed of said variety having been deposited under NCIMB Accession No. 42753.

US Pat. No. 10,653,081

METHOD AND APPARATUS FOR PROGRAMMING A DECODER-BASED IRRIGATION CONTROLLER

Rain Bird Corporation, A...

1. A decoder-based irrigation controller comprising:a controller housing;
a first microcontroller within the controller housing and configured to control operation of the decoder-based irrigation controller;
a decoder interface coupled to the first microcontroller, the decoder interface is configured to encode control data onto a power signal to be applied to a multi-wire control path to which each of a plurality of decoder units will be coupled;
a first connector coupled to the first microcontroller;
a removable cartridge configured to removably and detachably couple to the first connector to fit into the controller housing, wherein the removable cartridge comprises a second microcontroller; and
a handheld barcode reader, wherein the handheld barcode reader comprises an optical reader configured to read an optically readable pattern from each of the plurality of decoder units, wherein the handheld barcode reader is configured to transfer data read from the optically readable pattern of the plurality of decoder units to the second microcontroller of the removable cartridge, and wherein the data comprises an address of each of the plurality of decoder units.

US Pat. No. 10,653,080

HYBRID IRRIGATION TUBING

Responsive Drip Irrigatio...

1. A hybrid irrigation tube comprising:a lumen;
a microporous membrane, micropores of the microporous membrane configured to provide fluid communication between the lumen and an exterior surface of the hybrid irrigation tube;
a non-porous backer, the microporous membrane and the non-porous backer each extending lengthwise on the hybrid irrigation tube, the non-porous backer being connected to the microporous membrane at a first lengthwise weld area and a second lengthwise weld area; and
at least one drip emitter disposed in the non-porous backer, the at least one drip emitter configured to provide fluid communication between the lumen and the exterior surface of the hybrid irrigation tube, the microporous membrane having a first operational pressure range for fluid passage, the at least one drip emitter having a second operational pressure range for fluid passage, the first operational pressure range for fluid passage including pressures below the second operational pressure range for fluid passage.

US Pat. No. 10,653,079

UNDERGROUND TREE STAKE SYSTEM

Ginger Tree Innovations, ...

1. A saddle member for stabilizing a tree comprising:a w-unit formed from a first single length of material along a first axis and a second axis, the first axis and the second axis aligned in a substantial horizontal plane such that an intersection of the first axis and the second axis coincides with an approximate center of a trunk of the tree and the w-unit including:
a first arc positioned to the left of the first axis and below the second axis, the first arc opening in a first direction, the first direction towards the second axis;
a second arc positioned to the right of the first axis and below the second axis, the second arc opening in the first direction;
a third arc positioned along the first axis and above the second axis, the third arc opening in a second direction opposite the first direction and configured to couple to a first stake to secure the saddle member and the tree to a ground;
a first arm portion extending upward from the first arc at a first angle away from the first axis;
a second arm portion extending upward from the first arc at a second angle towards the first axis and downward from the third arc at a third angle away from the first axis;
a third arm portion extending upward from the second arc at a fourth angle towards the first axis;
a fourth arm portion extending upward from the second arc at a fourth angle away from the first axis; and
a stabilizer formed from a second single length of material, the stabilizer being folded at a first end and at a second end to provide a top portion, a first folded portion, and a second folded portion, wherein a first opening is provided between the top portion and the first folded portion and a second opening is provided between the top portion and the second folded portion, the first opening is configured to receive the first arm of the w-unit and the second opening is configured to receive the fourth arm of the w-unit; and
wherein the coupling of the stabilizer to the w-unit provides a first connection area to the left of the first axis and a second connection area to the right of the first axis, the first connection area defined by the first arc of the w-unit and the first folded portion of the stabilizer, the first connection area configured to couple to a second stake and the second connection area configured to couple to a third stake, wherein the second stake and the third stake secure the saddle member and the tree to the ground.

US Pat. No. 10,653,078

ANIMAL-INCURSION-RESISTANT RAISED BED GARDENING SYSTEM

W. Atlee Burpee Company, ...

1. A system for disposition on the ground for growing plants comprising:a base having a plurality of elongated sections configured to be disposed adjacent each other on the ground to form at least one hollow enclosure into which a growing medium can be disposed; and
a screened enclosure mounted on said base encircling said at least one hollow enclosure and comprising a frame and a plurality of screen members, said frame comprising a plurality of frame members connected to and extending upward from said base and receiving said screen members, said screen members comprising upper screen members and lower screen members, said upper screen members and said lower screen members being removably mounted on said frame.

US Pat. No. 10,653,077

PLANT PURIFICATION DEVICE AND CONTROL METHOD THEREOF

Beijing Center for Physic...

1. A plant purification device, characterized in that, it comprises a plant purification unit and a physicochemical purification unit with adjustable use efficiency, wherein, the physicochemical purification unit is communicated with the plant purification unit through an air supply channel; the plant purification device further comprises a control module, a contaminant concentration sensor for detecting concentration of indoor contaminants, an air speed detector for detecting air speed of gas entering the plant purification unit, and a fan arranged to receive gas from the physiochemical purification unit and to drive the received gas into the plant purification unit through the air supply channel, wherein, the control module is used to adjust the use efficiency of the physicochemical purification unit according to a signal of the contaminant concentration sensor, adjust rotating speed of the fan according to a detection signal of the air speed detector, and further control the air speed of the gas entering the plant purification unit.

US Pat. No. 10,653,076

METHOD FOR THE CULTIVATION OF PLANTS USING A CARRIER WITH A REMOVABLE SIDE SUPPORT STRUCTURE ARRANGED THEREON

Cultivation Systems B.V.,...

1. A method for the cultivation of a number of plants, comprising providing a carrier with apertures for said plants and providing a water supply,wherein, in a preparatory stage a growth medium is arranged in each of the apertures, wherein for each of the apertures at least two horizontally opposite sides of an upper part of the growth medium are sideways supported along a height by corresponding sides of a removable side support structure, removably arranged on a top side of the carrier, and the roots of a plant of said plants or a precursor thereof is placed in the growth medium,
wherein, in a first stage of growth of said plant or the precursor thereof, said carrier is provided above or on said water supply, and said plant or the precursor thereof is positioned at such a distance from said water supply that said roots of said plant or the precursor thereof are situated at a vertical distance from said water supply, at least a significant part of a moisture requirement of said plant or the precursor thereof is satisfied by an intermediate space between said carrier and said water supply and/or by said carrier, wherein said first stage of growth comprises at least a few days,
wherein, in a second, further stage of growth of said plant, at least 90% of the moisture requirement of said plant is satisfied directly by said water supply,
wherein, after the arranging of the growth medium in the apertures of the carrier, the removable side support structure is removed from the carrier while the growth medium remains supported in the apertures such that for each of the apertures the at least two opposite sides of the upper part of the growth medium are exposed, by the removal of the side support structure, and are grippable sideways to lift the growth medium along with the plant from the aperture for increasing the horizontal distance between said plants,
wherein, during the preparatory stage, after the placement of the plant or a precursor thereof in the growth medium, the plant or the precursor thereof is allowed to germinate in a germination room, wherein the removing of the removable side support structure from the top side of the carrier is done before the germination in the germination room.

US Pat. No. 10,653,074

FLOWERPOT MADE OF WASTE TIRES AND PREPARING METHOD THEREOF

1. A flowerpot made of waste tires, comprising: a suspended tire, a circular bottom plate, a hose clamp, a fixed disk and a supporting tube; wherein the fixed disk is fixed on a ground, the supporting tube is set up from a center of the fixed disk, the circular bottom plate has a through hole for passing through the supporting tube; the suspended tire, the circular bottom plate and the hose clamp are passed through by the supporting tube, wherein the hose clamp is sleeved on the supporting tube, so as to be fixedly locked on the supporting tube, the hose clamp tightly clamps a top portion of the supporting tube on the circular bottom plate without any slip; the suspended tire is provided above the circular plate; the suspended tire, the circular bottom plate and the hose clamp form a flowerpot body structure suspended on the supporting tube; the suspended tire is filled with soil for planting plants; a plurality of breathing holes are provided on the circular bottom plate to facilitate growth of roots of the plants; and side holes for facilitating irrigation are provided on a position of the supporting tube where the supporting tube is contacted with the suspended tire.

US Pat. No. 10,653,073

PLANT ILLUMINATION SYSTEM

VALOYA OY, Helsinki (FI)...

1. A lighting system, comprising:a housing defining a dark cavity with zero sunlight therein; and
at least one horticultural lighting fixture configured to emit a spectrum including
a first spectral feature in the form of a spectral peak having its peak wavelength in the blue wavelength range of 425-475 nm,
a second spectral feature in the form of a spectral valley having its base value in the cyan wavelength range of 475-500 nm,
a third spectral feature in the form of a broad-band spectral feature extending throughout the green wavelength range of 500-600 nm,
a fourth spectral feature in the form of a spectral peak having its peak wavelength in the red wavelength range of 625-675 nm, and
a fifth spectral feature in the far-red wavelength range of 700-800 nm,whereinthe fourth spectral feature has a maximum relative emission intensity that is the highest relative emission intensity within the spectrum,
the first spectral feature has a highest relative emission intensity that is non-zero but less than the maximum relative emission intensity,
the third spectral feature has a highest relative emission intensity that is non-zero but less than the maximum relative emission intensity,
the base value of second spectral feature is below all relative intensities of the third spectral feature, and
the fifth spectral feature has a non-zero relative intensity that is below the maximum relative intensity.

US Pat. No. 10,653,072

TABLETOP WREATH ASSEMBLY APPARATUS

MMP of Merrill, Inc., Me...

1. A wreath assembly apparatus for securing wreath materials to a wreath ring frame having a plurality of clips, the wreath assembly apparatus comprising:a base;
a first jaw and a second jaw operably coupled to each other and the base, wherein the first jaw and the second jaw are configured to bend one of the plurality of clips;
wherein the first jaw and the second jaw each have an upper end configured to engage the one of the plurality of clips and a lower end opposite the upper end;
a first gear coupled to the lower end of the first jaw; and
a second gear coupled to the lower end of the second jaw;
wherein the first and second gears are operatively coupled to one another such that rotation of the first gear in a first direction causes the second gear to rotate in a second direction and the upper end of the first jaw and the upper end of the second jaw to move toward each other to thereby bend the one of the plurality of clips;
wherein the lower end of the first jaw and the lower end of the second jaw lie in a first plane; wherein the upper end of the first jaw lies in a second plane that is offset from and parallel to the first plane; and
wherein the upper end of the second jaw lies in a third plane that is parallel to the first plane and offset from the first plane in a direction opposite the second plane.

US Pat. No. 10,653,071

DUAL AUGER BALER

1. A baler comprising:a frame;
a feed assembly coupled to the frame;
an auger housing defining a volume therein, wherein the volume of the auger housing is configured to receive crop material from the feed assembly during operation;
a bale case coupled to the frame and in operable communication with the volume of the auger housing, wherein the bale case is configured to apply a resistive force against a forming bale when positioned therein; and
a plurality of augers, each of which at least partially positioned within the volume and rotatable with respect to the auger housing, wherein each auger of the plurality of augers is configured to axially discharge crop material directly into the bale case.

US Pat. No. 10,653,070

DUAL AUGER BALER

1. A baler comprising:a frame;
a feed assembly coupled to the frame;
an auger housing coupled to the frame and in operable communication with the feed assembly, the auger housing having an exterior wall including a first open end, a second open end opposite the first open end, and defining a volume therein;
a first auger at least partially positioned within the volume and rotatable with respect to the auger housing about a first axis, wherein the first axis passes through the first open end and the second open end;
a second auger at least partially positioned within the volume and rotatable with respect to the auger housing about a second axis, wherein the second axis passes through the first open end and the second open end; and
a bale case coupled to the frame and in operable communication with the volume of the auger housing, wherein the bale case is configured to apply a resistive force against a forming bale positioned therein, and wherein both the first auger and second auger convey crop material directly into the bale case.

US Pat. No. 10,653,069

RESIDUE HANDLING SYSTEM FOR AN AGRICULTURAL HARVESTER

CNH Industrial America LL...

1. An agricultural harvester, comprising:a threshing and separating system for separating grain from non-grain crop material;
a residue handling system for receiving at least a portion of the non-grain crop material, the residue handling system including a chopper and a windrow arrangement, each having an inlet, and a door which is movable between a closed position which directs the non-grain crop material to the chopper and an open position which directs the non-grain crop material to the windrow arrangement, the residue handling system also including a feed roller positioned adjacent to and between the inlet of the chopper and windrow arrangement, the feed roller being rotatable in a first direction which directs the non-grain crop material to the chopper when the door is in the closed position, and a second direction which directs the non-grain crop material to the windrow arrangement when the door is in the open position; and
a cleaning system for grain configured to receive grain from the threshing and separating system, wherein the feed roller is movable between a first position adjacent to the inlet of the chopper and windrow arrangement, and a second position between the inlet of the chopper and an outlet of the cleaning system.

US Pat. No. 10,653,068

ADJUSTMENT AND SUSPENSION DEVICE FOR CONCAVES

CNH Industrial America LL...

1. An agricultural vehicle, comprising:a chassis; and
a threshing system supported by the chassis, and including:
a rotor;
a housing surrounding at least a portion of the rotor and including at least one concave located at a distance radially away from the rotor and having a concave frame which is configured for receiving a concave insert; and
a concave adjustment and suspension device connected to the housing and configured for adjusting a position of the concave frame and relieving an impact force acting on said at least one concave, said concave adjustment and suspension device including:
a torsion bar having a main section and at least one additional section being rotatably connected to the main section and operably coupled to the concave frame;
a drive operably coupled to the main section of the torsion bar and configured for rotating the torsion bar to adjust the position of the concave frame; and
at least one pneumatic spring mounted to the torsion bar and configured for compressing to relieve the impact force acting on said at least one concave; and
a first mounting bracket interconnected between said main section and a top of said at least one pneumatic spring and a second mounting bracket interconnected between said at least one additional section and a bottom of said at least one pneumatic spring.

US Pat. No. 10,653,067

CROP PACKAGE ACCUMULATOR

1. An accumulator for carrying bales received from a baling chamber of an agricultural baler, the accumulator and the agricultural baler configured to move in a direction of travel across a field to form bales, the accumulator comprising:a base frame mountable behind the baler;
a carriage mounted to the base frame to be movable relative to the base frame in a lateral direction, wherein the lateral direction is transverse to the direction of travel, the carriage having a platform and first and second upstanding side walls defining a crop package receiving area therebetween, the crop package receiving area having a fixed lateral width during all movement of the carriage relative to the base frame; and
at least one actuator mounted to the base frame and configured to move the carriage relative to the base frame or to move the carriage in response to a bale engaging one of the upstanding side walls, such that the platform and the first and second upstanding side walls are moved laterally relative to the base frame;
wherein the at least one actuator includes a bale separating member extending into the crop packaging receiving area, the bale separating member being fixed relative to the carriage and partitioning the crop package receiving area into sections.

US Pat. No. 10,653,065

GRAIN LOSS GAUGING SYSTEM FOR COMBINE HARVESTER

1. A grain loss gauging system in combination with a combine harvester that is able to cut a crop to be harvested, separate grain from chaff, capture the grain, and blow the chaff out of the combine harvester, the system comprising:a collection pan defining a receptacle having an open top for receiving material blown out of the combine harvester when deposited on the ground;
a remote arranged to generate a wireless trigger signal when triggered by an operator and arranged to be located remotely from the collection pan;
at least one magnetic device mounted on the collection pan and being arranged to magnetically retain the collection pan on a vehicle body of the combine harvester in a normal operating mode; and
a controller arranged to change operation of the at least one magnetic device from the normal operating mode to a triggered operating mode such that the at least one magnetic device is released from the vehicle body of the combine harvester together with the collection pan onto the ground in the triggered operating mode in response to receipt of the wireless trigger signal from the remote.

US Pat. No. 10,653,064

DRIVER ASSISTANCE SYSTEM

1. A mobile harvesting machine, comprising:at least one processor;
memory storing instructions executable by the at least one processor, wherein the instructions, when executed, cause the mobile harvesting machine to:
generate a user interface with an issue selection user input mechanism;
detect a user actuation of the issue selection user input mechanism indicative of a machine performance issue that is one of multiple machine performance options presented though the user interface;
select the machine performance issue based on the detection of the user actuation of the issue selection user input mechanism;
generate the user interface with a severity level user input mechanism;
detect a user actuation of the severity level user input mechanism indicative of a severity level that is one of multiple severity level options presented through the user interface as user selectable severity level options specifically associated with the selected machine performance issue;
select the severity level based on the detected user actuation of the severity level user input mechanism;
identify a solution that has a corresponding actions, based on a combination of the selected machine performance issue and the selected severity level; and
generate a control signal that controls the mobile harvesting machine based on the corresponding solution and its corresponding action.

US Pat. No. 10,653,063

MONITORING SYSTEM FOR AN AGRICULTURAL HARVESTER AND AGRICULTURAL HARVESTER

CNH Industrial America LL...

1. A combine harvester comprising:an aft portion;
a threshing and chopping system for separating a crop residue from the harvested crop;
a spreader assembly for discharging onto the field the crop residue received from the threshing and chopping system; and
a monitoring system comprising:
a plurality of sensors coupled to the aft portion of the combine harvester, the plurality of sensors:
receiving a plurality of response waves reflected from a portion of the crop residue that is discharged from the spreader assembly toward a discharge area before the portion of crop residue arrives at the discharge area, the discharge area being aft of the aft portion; and
sending a response signal representative of the plurality of response waves reflected from the portion of the crop residue, the reflected waves comprising a sequence of multiple reflections distributed over time; and
a processing unit in communication with the plurality of sensors, the processing unit executing steps of:
receiving the response signal from the plurality of sensors; and
processing the response signal to determine a reflected energy distribution from the portion of the crop residue representative of a distribution of the crop residue over the discharge area in a direction substantially perpendicular to a travel direction of the combine harvester.

US Pat. No. 10,653,062

ELECTRIC POWER EQUIPMENT

Honda Motor Co., Ltd., T...

1. Electric power equipment, comprising:a main body;
a work unit and wheels provided to the main body;
a work unit electric motor mounted on the main body to drive the work unit;
a travel electric motor mounted on the main body to drive the wheels;
a handle including a pair of left and right side rod members extending rearward from the main body;
a first rotary shaft supported at a rear end of one of the side rod members so as to be rotatable about a horizontal axis;
a second rotary shaft supported at a rear end of the other of the side rod members so as to be rotatable about a horizontal axis aligned with the horizontal axis about which the first rotary shaft is rotatable;
a lever support collar member fitted on an outer circumference of the first rotary shaft so as to be rotatable around the first rotary shaft;
a first operation lever having one end connected with an outer end of the first rotary shaft in a force transmitting relationship and another end connected with an outer end of the second rotary shaft so as to be rotatable relative to the second rotary shaft about a central axis of the second rotary shaft;
a second operation lever having one end connected with the lever support collar member at a position displaced relative to a central axis of the first rotary shaft so as to be rotatable with the lever support collar member and another end connected with the outer end of the second rotary shaft at a position displaced relative to the central axis of the second rotary shaft in a force transmitting relationship;
a first motor drive command unit disposed at a laterally central position between the rear ends of the side rod members so as to be operable by an inner end of the first rotary shaft to generate a command signal for controlling driving of one of the work unit electric motor and the travel electric motor;
a second motor drive command unit disposed at a laterally central position between the rear ends of the side rod members so as to be operable by an inner end of the second rotary shaft to generate a command signal for controlling driving of the other of the work unit electric motor and the travel electric motor; and
a controller configured to control electric power supplied from a power source to the work unit electric motor and the travel electric motor based on the signals from the first motor drive command unit and the second motor drive command unit.

US Pat. No. 10,653,061

METHOD AND APPARATUS FOR HARVESTING CROP MATERIAL

1. A crop harvesting machine configured to cut crop material and to transfer the cut crop material, the crop harvesting machine comprising:a cutterbar supported by a frame, the cutterbar including a plurality of rotary cutters disposed along an axis which is transverse to a forward working direction of the crop harvesting machine, each of the plurality of rotary cutters includes at least one rotary cutter knife mounted thereto, each of the rotary cutter knives defining a leading edge at which the crop is cut by the rotary cutter knives, and a trailing edge spaced from the leading edge along the working direction and disposed toward the rearward location of the frame, a sequence of adjacent rotational centerlines of the rotary cutters defines a rotary cutter longitudinal zone, wherein each of the rotary cutters includes an inclined leading portion extending downwardly relative to and away from the rotational centerline thereof towards the leading edge, further wherein each of the rotary cutters includes an inclined trailing portion extending downwardly relative to and away from the rotational centerline thereof towards the trailing edge;
an undershot rotating element supported by the frame for rotation about a rotational axis, wherein the rotational axis of the undershot rotating element is located above at least a portion of the cutterbar and the rotational axis is further disposed between the rotary cutter longitudinal zone and the trailing edge, the undershot rotating element is located above the inclined trailing portions of the plurality of rotary cutters, the undershot rotating element is configured to rotate about the rotational axis to move cut crop material between the undershot rotating element and the plurality of rotary cutters; and
an overshot rotating element supported by the frame for rotation about a rotational axis wherein the rotational direction of the overshot rotating element is in a direction opposite to the rotational direction of the undershot rotating element, the undershot rotating element being spaced apart from and forward of the overshot rotating element as measured along a longitudinal axis of the crop harvesting machine such that a rear edge of the undershot rotating element is spaced apart from and forward of a forward edge of the overshot rotating element to provide a path for the cut crop between the undershot rotating element and the overshot rotating element.

US Pat. No. 10,653,060

ELONGATE SICKLE KNIFE

CNH Industrial America LL...

1. A header for an agricultural vehicle, the header comprising:a header frame having a leading edge; and
an elongate sickle knife mounted along the leading edge of the header frame;
an actuator for reciprocally moving the elongate sickle knife in its longitudinal direction relative to the header frame between a first position and a second position over an intermediate position; and
at least one accumulator extending between the header frame and the elongate sickle knife to accumulate energy during a first movement of the elongate sickle knife from the intermediate position towards at least one of the first position and the second position, the at least one accumulator accumulating energy at all times during the first movement, wherein the actuator decelerates the sickle knife and during deceleration energy is accumulated in the at least one accumulator, and to release accumulated energy during a second movement of the elongate sickle knife opposite the first movement.

US Pat. No. 10,653,059

PIVOTING ACTION LOW PROFILE SICKLE DRIVE

CNH Industrial America LL...

1. A sickle drive for a crop harvesting machine, the sickle drive comprising:a first input element supported for rotation about a generally upstanding first rotational axis and configured for connection in rotationally driven relation to a rotary power source;
a first eccentric element connected to the first input element for rotation eccentrically about the first rotational axis;
a first pivot element supported for rotation about a generally upstanding first pivotal axis, the first pivot element comprising a first pivot arm; and
a first drive arm having a first end connected to the first eccentric element for rotation therewith eccentrically about the first rotational axis and a second end pivotally connected to the first pivot element such that the eccentric rotation of the first eccentric element causes the first drive arm to reciprocatingly pivot the first pivot element about the first pivotal axis,
wherein the first pivot arm is pivotably connected to a bottom end of the first drive arm and extends upwardly terminating at a position above the first drive arm.

US Pat. No. 10,653,057

MOVING ROBOT AND CONTROL METHOD THEREOF

LG ELECTRONICS INC., Seo...

1. A robot comprising:a body;
a driving unit to drive the body such that the body travels within an operation region; and
a controller to generate map information corresponding to an operation region, the controller setting first information corresponding to at least one reference line using coordinate information corresponding to vertices included in a polygon forming the operation region, and the controller, using the first information, setting second information corresponding to a plurality of regions such that the operation region is divided into the plurality of regions,
wherein the controller, using the second information, controls the driving unit such that the body travels according to a preset movement pattern for each of the plurality of divided regions, and
wherein when a maximum length of any one of the divided regions along a preset traveling direction is greater than a predetermined maximum traveling distance value, the controller resets the second information such that the divided region is divided into a plurality of sub-regions.

US Pat. No. 10,653,056

SEED METERING SYSTEM AND METHOD OF OPERATING THE SAME

1. A seed metering system for selectively metering a plurality of seeds, the seed metering system comprising:a seed tank including a seed tank outlet;
a number of row units, wherein each and every row unit of the number of row units comprises:
a singulating meter in selective communication with the seed tank outlet,
a bypass conduit in selective communication with the seed tank outlet, and
an outlet common to and downstream of the singulating meter and the bypass conduit; and
a volumetric metering system positioned upstream of the number of row units and operable to volumetrically meter the plurality of seeds,
wherein the seed metering system is operable in a first mode of operation in which the seed tank outlet communicates with each singulating meter via the volumetric metering system to singulate the plurality of seeds, and
wherein the seed metering system is operable in a second mode of operation in which the seed tank outlet communicates with each bypass conduit via the volumetric metering system and seeds are not singulated.

US Pat. No. 10,653,055

AGRICULTURAL SEEDER IMPLEMENTS

1. An agricultural seeder implement, comprising:an opener including a trailing extremity, a leading extremity, and a lower extremity including an undersurface extending between the trailing extremity and the leading extremity; and
a seed boot connected to the opener, the seed boot extends beyond the opener at the lower extremity, and the undersurface of the opener and an upper surface of the seed boot define a channel extending forwardly under the lower extremity of the opener from an inlet proximate to the trailing extremity of the opener to an outlet proximate to the leading extremity of the opener.

US Pat. No. 10,653,054

METHOD FOR PRODUCING A BIODIGESTER REACTOR AND MEMBRANE TEMPLATE

BUEN MANEJO DEL CAMPO, S....

1. A method of manufacturing a biodigester reactor from a rectangular membrane template, the method comprising the steps of:making cuts, in a first pair of opposite ends of the rectangular template, for removal of membrane forming two quadrilaterals per said each opposite end, wherein each quadrilateral includes two first non-consecutive parallel sides and being also parallel to a second pair of opposite ends of the rectangular template and a third side being orthogonal to the two first non-consecutive parallel sides located over a corresponding edge of rectangular template, and wherein a spacing distance between said quadrilaterals is the same distance as the sum of the spacing distances between each quadrilateral and a closest end of the second pair of ends of the rectangular template;
joining an edge of an end of the second pair of ends of the rectangular template to an edge of the other end of the second pair of ends of the rectangular template, thereby forming a sleeve;
joining each fourth side of a quadrilateral to an adjacent side of a fourth side, such that an adjacent side of a quadrilateral is the closest side to an adjacent side of another quadrilateral, thereby partially sealing the sleeve; and
joining remaining edges of the first pair of opposite ends, thereby totally sealing the sleeve.

US Pat. No. 10,653,053

SYSTEM FOR APPLYING DOWN PRESSURE IN A COULTER ASSEMBLY

CNH Industrial Canada, Lt...

1. A coulter assembly for an agricultural implement comprising:a support structure;
a disc blade rotatably mounted to the support structure;
a spring assembly having a first end coupled to the support structure and a second end configured to mount to a rockshaft, wherein the spring assembly is configured to urge the disc blade into soil, the spring assembly comprises a variable rate spring having multiple spring constants, and the spring rate of the variable rate spring is configured to vary in response to compression of the variable rate spring; and
an actuator configured to adjust a position of the support structure relative to the soil.
US Pat. No. 10,655,075

HYDROTREATING AND DEWAXING PROCESS

SHELL OIL COMPANY, Houst...

1. A process for hydrotreating and dewaxing a hydrocarbon feedstock that is a gas oil comprising sulfur-containing compounds and boiling in the range of from 170-450° C., wherein the process comprises the steps of:(a) hydrotreating the feedstock under hydrotreating conditions within a first reaction zone containing a first hydrotreating catalyst comprising a Group VII metal to metal compound and a Group VIB metal to metal compound on a porous catalyst support to obtain a first stage hydrotreated effluent having a sulfur content of at most 150 ppmw and a first stage effluent cloud point;
(b) introducing at least part of the first stage hydrotreated effluent into a second reaction zone in which the first stage hydrotreated effluent is subjected to a series of alternating dewaxing steps and hydrotreating steps, which three or more dewaxing steps are carried out under catalytically dewaxing conditions and three or more hydrotreating steps are carried out under hydrotreating conditions, wherein the first step in the series of alternating dewaxing and hydrotreating steps is a dewaxing step and the last step in the series of alternating dewaxing and hydrotreating steps is a hydrotreating step, and each dewaxing step is carried out with a volume of 45 cubic meter (m3) of a dewaxing catalyst which comprises a Group VIII metal hydrogenation component, dealuminated aluminosilicate zeolite crystallites, having crystallite sizes in the range of from 0.1 micron to 100 microns, and a low acidity refractory oxide binder material which is essentially free of alumina, and the hydrotreating steps are carried out with a second hydrotreating catalyst, wherein total volume of beds of the second hydrotreating catalyst is in the range of from 10% to 65% of the total volume of the beds of dewaxing catalyst; and
(c) obtaining from step (b) a second stage effluent having a second stage effluent cloud point that is lower than the first stage effluent cloud point.
US Pat. No. 10,654,820

CRYSTAL FORM OF TASIMELTEON

ZHEJIANG JINGXIN PHARMACE...

1. A crystal form I of Tasimelteon: characterized by an X-ray powder diffraction spectrum, using CuK? radiations, and represented by a 2? angle having diffraction peaks at least at 7.2°±0.2°, 7.9°±0.2°, 10.6°±0.2°, 14.4°±0.2°, 15.9°±0.2°, 17.3°±0.2°, 21.0°±0.2°, 23.2°±0.2, and 24.4°±0.2°.
US Pat. No. 10,655,076

ASSORTED CO-STAGING AND COUNTER STAGING IN HYDROTREATING

INDIAN OIL CORPORATION LI...

1. A co and counter stage hydrotreating process for deep desulfurization and deep hydro-treating of diesel range hydrocarbons, comprising:(a) segregating a full range diesel feed stream into a first feed stream and a second feed stream;
(b) mixing and preheating the second feed stream with water and amine washed recycle hydrogen and passing through a first hydrotreating zone of a first stage hydrotreating to obtain an effluent;
(c) mixing the effluent obtained in step (b) with the first feed stream and the recycle hydrogen and passed to a second hydrotreating zone of the first stage hydrotreating to obtain an another effluent;
(d) separating the effluent obtained in step (c) in a liquid part and a gaseous part; wherein the gaseous part comprises of bulk of hydrogen with hydrogen sulfide and ammonia;
(e) cooling and washing the gaseous part obtained in step (d) with water and amine to obtain recycle hydrogen; wherein the recycle hydrogen comprises of bulk of hydrogen with reduced hydrogen sulphide and ammonia;
(f) recycling the recycle hydrogen obtained in step (e) to the first and the second hydrotreating zone of the first stage hydrotreating;
(g) flashing the liquid part obtained in step (d) to obtain a top flashed liquid and a bottom flashed liquid;
(h) recovering the top flashed liquid obtained in step (g) as diesel product;
(i) dividing the bottom flashed liquid obtained in step (g) in a first part and a second part; wherein the first part is recovered as diesel product;
(j) mixing the second part obtained in step (i) with make-up hydrogen and passed to a second stage hydrotreating to obtain another effluent;
(k) mixing the effluent obtained in step (j) with the second feed stream obtained in step (a).
US Pat. No. 10,653,797

COMPOUNDS AND COMPOSITIONS FOR TARGETING BRAIN INJURIES AND METHODS OF USE THEREOF

SANFORD BURNHAM PREBYS ME...

1. A method of selectively targeting a cargo composition to a site of nervous system injury in a subject, the method comprising:administering a composition to a subject having a nervous system injury, the composition comprising a cargo composition linked or conjugated to a peptide comprising the amino sequence CAQK (SEQ ID NO:4),
wherein the composition selectively homes to a site of the nervous system injury in the subject thereby selectively targeting the cargo composition to the site of the nervous system injury.
US Pat. No. 10,654,821

GRISEOFULVIN COMPOUND

Daiichi Sankyo Company, L...

1. A pharmaceutical composition comprising a compound or a pharmacologically acceptable salt thereof selected from the following group as an active ingredient:(2S,5?R)-7-chloro-6-(2-hydroxyethoxy)-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-3?,4-dimethoxy-6-(2-methoxyethoxy)-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-3?,4-dimethoxy-5?-methyl-6-(1-methylpyrazol-3-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-6-(1-ethylpyrazol-3-yl)-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-3?,4-dimethoxy-5?-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-3?,4-dimethoxy-5?-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-3?,4-dimethoxy-5?-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-6-[5-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-6-[5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-4-ethoxy-6-[5-(1-hydroxy-1-methyl-ethyl)-1,3,4-oxadiazol-2-yl]-3?-methoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-4-ethoxy-6-[S-[(1S)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3?-methoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-6-[3-(1-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3?,4-dimethoxy-5?-methyl-spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-4-(2-hydroxyethoxy)-3?-methoxy-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione,
(2S,5?R)-7-chloro-4-(2-hydroxyethoxy)-3?-methoxy-5?-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione, and
(2S,5?R)-7-chloro-4-(2-hydroxyethoxy)-3?-methoxy-5?-methyl-6-(5-methyl-1,2,4-oxadiazol-3-yl)spiro[benzofuran-2,4?-cyclohex-2-ene]-1?,3-dione.
US Pat. No. 10,654,822

COMPOSITION AND RODENTICIDAL BAIT COMPRISING FLOCOUMAFEN, AND PROCESS FOR CONTROLLING TARGET RODENT PESTS

LIPHATECH, Pont-du-Casse...

1. Composition comprising flocoumafen, wherein;said composition comprising flocoumafen either includes:a non-zero amount of a configurational stereoisomer of flocoumafen, named enantiomer E4, said enantiomer E4 being one of the configurational stereoisomers of one of the two diastereoisomers, said diastereoisomer D1,4, of flocoumafen, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, said enantiomer E4 having, by chromatographic analysis of a flocoumafen composition comprising four configurational stereoisomers of flocoumafen, a retention time t4 having a value such that t1 alternatively said composition comprising flocoumafen comprises a non-zero amount of a configurational stereoisomer of flocoumafen, named enantiomer E1, said enantiomer E1 having, by chromatographic analysis of a flocoumafen composition comprising four configurational stereoisomers of flocoumafen, under the conditions mentioned below, a retention time t1 having a value such that t1 the chromatographic analysis being performed at a temperature of 23.5° C. and under the conditions below:
on a high-pressure liquid chromatography column of dimensions 150×2 mm, and comprising a chiral stationary phase constituted of particles of tris(4-chloro-3-methylphenyl carbamate) cellulose, said particles having a mean size of 3 ?m and having a mean pore size of 1000 ?;
using, as liquid mobile phase, a mixture formed from acetonitrile (A) and water comprising 0.1% by volume of formic acid (B), with an AB volume ratio of 92/8 and with a flow rate of the liquid mobile phase in the chromatography column of 0.25 mL/minute;
by injection into the chromatography column of a volume of 1 ?L of flocoumafen composition at a concentration of 1 ?g of flocoumafen per millilitre of acetonitrile.
US Pat. No. 10,653,799

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PROTEIN

1. An isolated nucleic acid comprising:a) a coding region encoding a therapeutic polypeptide, wherein the coding region does not code for histone polypeptides, reporter polypeptides selected from EGFP and Luciferase, or marker or selection polypeptides selected from alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT),
b) at least one histone stem-loop, and
c) a poly(A) sequence or a polyadenylation signal.
US Pat. No. 10,654,823

TRANSPARENT GLASSY CANNABINOID COMPOSITIONS

Scientific Holdings, LLC,...

1. A method for preparing a cannabinoid composition, the method comprising:(i) adding crystalline THCA powder to raw cannabis distillate;
(ii) chilling to below 0° C.;
(iii) mixing the crystalline THCA powder with the raw cannabis distillate; and
(iv) repeating said chilling and repeating said mixing to obtain a homogeneous amorphous powder;to obtain the cannabinoid composition.
US Pat. No. 10,658,665

LITHIUM ION SECONDARY BATTERY HAVING A NEGATIVE ELECTRODE ACTIVE MATERIAL FORMED OF A GRAPHITE MATERIAL AND A CONDUCTIVE CARBON MATERIAL DIFFERENT FROM THE GRAPHITE MATERIAL

TOYOTA JIDOSHA KABUSHIKI ...

1. A lithium ion secondary battery comprising:an electrode body including a positive electrode provided with a positive electrode active material layer on a positive electrode collector, and a negative electrode provided with a negative electrode active material layer on a negative electrode collector; and
a non-aqueous electrolyte,
the negative electrode active material layer including: a negative electrode active material, and a conductive carbon material which is different from the negative electrode active material,
wherein the conductive carbon material comprises at least one kind of carbon black,
the negative electrode active material consists essentially of a graphite material coated at least partially with a layer of amorphous carbon,
the negative electrode active material has a bulk density of 0.5 g/cm3 or more and 0.7 g/cm3 or less, and a BET specific surface area of 2 m2/g or more and 6 m2/g or less,
the conductive carbon material has a bulk density of 0.4 g/cm3 or less, and a BET specific surface area of 50 m2/g or less, and
the negative electrode active material layer is obtained by (i) intimately mixing particles of the graphite material coated at least partially with the layer of amorphous carbon, particles of the at least one kind of carbon black, a binder, and a solvent to obtain a composition and (ii) depositing the composition on the negative electrode current collector, such that the particles of the at least one kind of carbon black are present in the negative electrode active material layer as particles that are separate and distinct from the particles of the graphite material coated at least partially with the layer of the amorphous carbon.
US Pat. No. 10,653,800

OLIGONUCLEOTIDE-BASED PROBES FOR DETECTION OF BACTERIAL NUCLEASES

University of Iowa Resear...

1. A probe for detecting a microbial endonuclease comprising an oligonucleotide of 2-30 nucleotides in length, a fluorophore operably linked to the oligonucleotide, and a quencher operably linked to the oligonucleotide, wherein the oligonucleotide comprises a chemically modified purine comprising a 2? substituted sugar and is capable of being cleaved by a microbial nuclease but not by a mammalian nuclease.
US Pat. No. 10,653,801

TARGETING PEPTIDES AND METHODS OF USE

CASE WESTERN RESERVE UNIV...

1. A method of determining cancer aggressiveness in a subject having or suspected of having cancer, the method comprising:administering to the subject a molecular probe comprising at least one targeting peptide coupled to a detectable moiety, the targeting peptide binding to EDB-FN or EDA-FN and comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30; and
detecting the molecular probes in the subject, wherein the amount of the probe detected is indicative of the aggressiveness of the cancer.
US Pat. No. 10,653,802

PHOTOLUMINESCENT HYDROGEL

New Jersey Institute of T...

1. A photoluminescent dopant-free hydrogel having biodegradable properties, comprising:a dopant-free polyester-based biodegradable photoluminescent hydrogel defined as a citric acid and hexaethylene glycol based polyester oligomer-serine-ethyl thioglycolate-polyethylene glycol (CHPO-Ser-ET-PEG) hydrogel, the hydrogel is synthesized by:
(1) synthesizing a fluorescent oligomer from reacting an amino acid Serine (Ser), a citric acid, and a hexaethylene glycol to form a citric acid and hexaethylene glycol serine based polyester oligomer (CHPO-Ser), followed by a transesterification reaction with a Candida antarctica Lipase B (CALB) first catalyst to functionalize a thiol containing compound ethyl thioglycolate (ET) to the citric acid and the hexaethylene glycol serine based polyester oligomer (CHPO-Ser),
the fluorescent oligomer has at least 5 to 7 thiol groups singularly conjugated thereon through the CALB catalyzed transesterification reaction; and
(2) reacting the oligomer with a multiple arm polyethylene glycol (PEG) second catalyst to form the hydrogel; and
wherein the hydrogel emits a fluorescence under visible light excitation with emissions up to 720 nm.
US Pat. No. 10,653,803

CELLULAR MICROMOTORS AND USES THEREOF

The Regents of the Univer...

1. A method for controlling movement of a red blood cell micromotor comprising:selectively exposing a red blood cell having a plurality of magnetic particles contained therein to an external magnetic field; and
propelling the red blood cell in a controlled manner using acoustics, wherein the external magnetic field influences and guides movement of the red blood cell.
US Pat. No. 10,653,804

SOLVENT-FREE GADOLINIUM CONTRAST AGENTS

Inventure, LLC, Southbur...

1. A method of making a gadolinium contrast agent, comprising:reacting a ligand with Gadolinium Oxide in water at a reaction temperature and for a reaction time of at least twelve hours to thereby provide a Gadolinium:ligand complex; and
reacting the Gadolinium:ligand complex with meglumine to thereby provide a complex of Gd(III) ion, ligand and meglumine in an aqueous formulation;
wherein:
the aqueous formulation comprises not more than 0.025% by weight of free ligand;
the aqueous formulation comprises less than 100 parts per million of free Gd(III) ion; and
the aqueous formulation comprises less than 50 parts per million of non-aqueous solvent.
US Pat. No. 10,655,088

SOLID POLYMER COMPOSITION OBTAINED BY POLYMERIZATION OF AN ACID GROUP-CONTAINING MONOMER IN THE PRESENCE OF A POLYETHER COMPOUND

BASF SE, (DE)

1. A method for at least partially ensheathing a liquid or solid washing and cleaning composition, comprising utilizing a polymer composition in solid form obtained by a process comprising:a) providing a monomer composition M) comprising
A) at least one ?,?-ethylenically unsaturated carboxylic acid, and
B) less than 0.1% by weight, based on the total weight of the monomer composition M), of crosslinking monomers having two or more polymerizable ?,?-ethylenically unsaturated double bonds per molecule,
where component A) is optionally partly or fully replaced by C) at least one unsaturated sulfonic acid or unsaturated phosphonic acid,
b) subjecting the monomer composition M) provided in step a) to a free-radical polymerization in the presence of at least one polyether component PE), which does not have any copolymerizable double bonds, selected from the group consisting of polyetherols having a number-average molecular weight of at least 200 g/mol and the mono- and di-(C1-C6-alkyl) ethers thereof, surfactants containing polyether groups and mixtures thereof.
US Pat. No. 10,655,089

DETERGENT COMPOSITION

RECKITT BENCKISER FINISH ...

1. An automatic dishwashing detergent composition comprising;0.01% wt to 2% wt of a subtilisin variant having the amino acid sequence set forth in SEQ ID NO 1;
5% wt to 15% wt of a percarbonate bleach;
20% wt to 80% wt of aminocarboxylates; and
0.01% wt to 2% wt of organophosphonic acids or salts thereof,
wherein the automatic dishwashing detergent composition is fully enveloped by a water soluble or water dispersible package,
wherein the water soluble or water dispersible package has a plurality of compartments, and
wherein the water soluble or water dispersible package comprises polyvinyl alcohol.
US Pat. No. 10,656,113

BIOSENSOR SYSTEMS FOR DETERMINING ANALYTE CONCENTRATION BASED ON COMPLEX INDEX FUNCTIONS

Ascensia Diabetes Care Ho...

1. A biosensor system, for determining an analyte concentration in a fluid sample, comprising:a test sensor having a sample interface adjacent to a fluid reservoir, wherein the test sensor generates at least one output signal from the sample; and
a measurement device having a processor, a sensor interface, and a storage medium, wherein the processor is connected to the sensor interface, wherein the sensor interface has electrical communication with the sample interface, and the processor has electrical communication with a storage medium,
wherein the processor determines at least one output signal value from the output signal received from the sensor interface, wherein the at least one output signal value represents an unknown concentration of the analyte in the sample,
wherein the processor determines at least one ?S value from at least a complex index function stored in the storage medium,
wherein the at least one ?S value represents a slope deviation of a slope of a correlation between analyte concentration and the at least one output signal from a hypothetical slope of a perfect correlation between analyte concentration and output signals, the correlation between analyte concentration and the at least one output signal determined from at least one previously determined reference correlation between previously determined reference output signal values and reference sample analyte concentration values, the reference sample analyte concentration values obtained from a reference instrument,
wherein the complex index function includes at least two terms, wherein each of the at least two terms is modified by a weighing coefficient, wherein at least one of the at least two terms modified by the weighing coefficients is responsive to a bias between the reference correlation of analyte concentrations and the at least one output signal, wherein the complex index function is responsive to at least one error parameter, wherein the weighing coefficients are numerical values other than one or zero, and
wherein the processor determines the analyte concentration in the sample from the output signal value and a slope compensation equation stored in the storage medium, wherein the slope compensation equation adjusts a slope of the at least one reference correlation with the at least one determined ?S value.
US Pat. No. 10,653,810

READY TO USE BIODEGRADABLE AND BIOCOMPATIBLE DEVICE AND A METHOD OF PREPARATION THEREOF

Datt Life Sciences Privat...

1. A method for making a hemostat device, the method comprising:preparing a homogenous solution of gelatin and chitosan by at least
adding gelatin to water to form a gelatin solution,
adding an acid to the gelatin solution to provide an acidified gelatin solution, and
adding chitosan to the acidified gelatin solution to form the homogenous solution of gelatin and chitosan;
air drying the homogenous solution of gelatin and chitosan to provide an air dried scaffold;
processing the air dried scaffold to provide a porous sponge defining a porous gelatin-chitosan polyelectrolyte matrix structure having opposing first and second porous faces, and a plurality of vesicular voids between the first and second porous faces, the first porous face having pores greater in size than pores in the second porous face;
the porous gelatin-chitosan polyelectrolyte matrix structure configured to provide, between the opposing first and second porous faces, a differential and regulated porosity on a same platform in a molecularly integrated matrix;
the pores of the second porous face configured to prevent loss of blood components, and the pores of the first porous face configured to permit blood to enter the hemostat device;
loading the porous sponge with a clotting agent by exposing the porous sponge to the clotting agent in an aqueous solution so that the clotting agent is carried internally by the plurality of vesicular voids in the porous gelatin-chitosan polyelectrolyte matrix structure and configured to clot blood entering the porous gelatin-chitosan polyelectrolyte matrix structure from the first porous face; and
drying the loaded porous sponge.
US Pat. No. 10,655,090

DETERGENT COMPOSITIONS AND USES OF THE SAME

1. A detergent composition comprising:(a) a polypeptide having protease activity comprising or consisting of the amino acid sequence of SEQ ID NO:1, or a variant thereof which exhibits protease activity, wherein the number of modifications in said protease variant relative to the amino acid sequence of SEQ ID NO: 1 is 1 to 4;
(b) a polypeptide having alpha-amylase activity; and
(c) a surfactant,
or concentrate or additive for making the same.
US Pat. No. 10,654,835

COMPOUNDS AND METHODS FOR INHIBITING JAK

Dizal (Jiangsu) Pharmaceu...

22. A pharmaceutical composition, which comprises the solvate form of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
US Pat. No. 10,653,812

METHOD OF PREPARING SUPERABSORBENT POLYMER

LG Chem, Ltd., (KR)

1. A method of preparing a superabsorbent polymer, the method comprising the steps of:performing crosslinking polymerization of water-soluble ethylene-based unsaturated monomers having acidic groups which are at least partially neutralized in the presence of an internal crosslinking agent to form a water-containing gel polymer including a crosslinked polymer;
drying, pulverizing, and size-sorting the water-containing gel polymer to form a base polymer powder;
performing surface-crosslinking of the base polymer powder using a surface-crosslinking solution including one or more surface-crosslinking agents selected from the group consisting of an alkylene carbonate having 2 to 5 carbon atoms, diol, triol, or polyol containing an alkyl group having 2 to 12 carbon atoms or polyethylene glycol having 2 to 12 carbon atoms, and diepoxy, triepoxy, or polyepoxy containing an alkyl group having 2 to 12 carbon atoms or polyethylene glycol having 2 to 12 carbon atoms, in the presence of first alumina particles; and
adding second alumina particles to the surface-crosslinked base polymer powder and then mixing them with each other,
wherein the first alumina is included in an amount of 0.01 to 0.2 parts by weight with respect to 100 parts by weight of the base polymer powder, and the second alumina is included in an amount of 0.05 to 0.3 parts by weight with respect to 100 parts by weight of the surface-crosslinked superabsorbent polymer powder.
US Pat. No. 10,653,813

REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF

University of Utah Resear...

1. An associative liquid adhesive complex coacervate, wherein the liquid adhesive complex coacervate comprises (a) at least one polycation, (b) at least one polyanion, and (c) a reinforcing component comprising a water-insoluble solid.
US Pat. No. 10,655,093

COMPACTED LIQUID LAUNDRY DETERGENT COMPOSITION

1. A water-soluble unit dose article comprising a water-soluble film and a liquid laundry detergent composition comprising;a. a liquid phase;
b. between about 0.5% and about 15% by weight of the liquid detergent composition of a solid cellulosic polymer,
wherein the solid is dispersed within the liquid phase and wherein the water-soluble solid phase is defined as the solid obtained when the liquid laundry detergent composition is centrifuged at about 1200 G for about 10 mins; and
wherein the liquid phase comprises between about 5% and about 40% by weight of the liquid of an alcohol selected from the group consisting of ethylene glycol, 1,3 propanediol, 1,2 propanediol, tetramethylene glycol, pentamethylene glycol, hexamethylene glycol, 2,3-butane diol, 1,3 butanediol, diethylene glycol, triethylene glycol, polyethylene glycol, glycerol formal, dipropylene glycol, polypropylene glycol, dipropylene glycol n-butyl ether, and mixtures thereof; and
wherein the composition comprises between about 0.5% and about 50% by weight of the composition of water; and
from about 10% to about 30% by weight of the composition of a non-amine neutralized linear alkylbenzene sulphonate and wherein the liquid laundry detergent composition comprises less than 10% by weight of the liquid laundry detergent composition of an amine-neutralised anionic surfactant; and
from 0% to about 25% by weight of the composition of a non-ionic surfactant;
wherein the composition comprises between 0 and 0.1% by weight of the composition of a hydroxyl-containing amine; and wherein the liquid laundry detergent composition exhibits a viscosity of less than 1560 mPa·s at 0.05 s-1 and less than 870 mPa·s at 1000 s-1,
wherein the water-soluble film comprises an aversive agent, wherein the aversive agent is a bittering agent selected from naringin, sucrose octaacetate, quinine hydrochloride, denatonium benzoate, or mixtures thereof.
US Pat. No. 10,653,814

PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES

ALLERGAN PHARMACEUTICALS ...

1. A method of enhancing tissue in-growth and/or tissue re-growth in a patient in need thereof, comprising administering to the patient a tissue compatible composition comprising a cross-linked protein matrix, wherein the cross-linked protein matrix comprises:i) a protein selected from the group consisting of tropoelastin and albumin;
ii) a hyaluronic acid cross-linking molecule comprising one or more carboxyl groups; and
iii) at least one intermolecular cross-linkage comprising an amide bond between an amine of the protein and a carboxyl group of the hyaluronic acid cross-linking molecule.
US Pat. No. 10,654,582

FUEL SEPARATION UNIT FOR INERT GAS GENERATING SYSTEM

Hamilton Sundstrand Corpo...

1. An inert gas generating system comprising:a source of a gaseous mixture;
a fuel separation unit configured to receive a portion of the gaseous mixture from the source, the fuel separation unit comprising a silicone-based membrane configured to separate the gaseous mixture into a condensable gas portion and a non-condensable gas portion;
a pressure differential generator in fluid communication with a permeate side of the silicone-based membrane, wherein the pressure differential generator is configured to create a partial pressure gradient across the silicone-based membrane; and
a catalytic oxidation unit configured to receive the condensable gas portion and to produce an inert gas.
US Pat. No. 10,655,094

METHOD OF MAKING ALCOHOL CONCENTRATE

1. A method for making a solution that can be used to generate a beverage, the method comprising:creating a first solution, wherein creating the first solution comprises performing a first fermentation process on a first wort;
creating a first bottom product by removing a first top product from the first solution, wherein the first top product includes alcohol removed from the first solution;
creating a second solution, wherein creating the second solution comprises adding a second wort to the first bottom product and performing a second fermentation process on the second wort in the first bottom product; and
creating a second bottom product by removing a second top product from the second solution, wherein the second top product includes alcohol removed from the second solution.
US Pat. No. 10,653,815

MESH COMPOSITIONS AND METHODS OF PRODUCTION

LifeCell Corporation, Ma...

1. A method of producing a surgical material, comprising:providing a synthetic material substrate;
selecting a collagen-containing tissue matrix;
creating a slurry with the collagen-containing tissue matrix, wherein creating the slurry comprises:
subjecting a portion of the collagen-containing tissue matrix to an acid swelling process to produce an acid-swelled tissue matrix, resulting in (i) the acid-swelled tissue matrix including the portion of the collagen-containing tissue matrix and (ii) a remainder portion of the collagen-containing tissue matrix; and
mixing the acid-swelled tissue matrix with the remainder portion of the collagen-containing tissue matrix to produce a slurry having between 5% and 35% by volume of the acid-swelled tissue matrix; and
embedding the synthetic material substrate in the slurry.
US Pat. No. 10,653,816

CONFORMAL COATING OF CELLS FOR IMMUNOISOLATION

CONVERGE BIOTECH INC., M...

1. A method of conformally coating a biomaterial with a coating material, comprising the steps of:a) injecting a water phase comprising the biomaterial and the coating material within a coaxial oil phase in a coating device that allows for a transition from dripping to jetting and flow elongation of the water phase within the oil phase, and wherein the diameter of the biomaterial is larger than the diameter of the water phase jet;
b) allowing for breakup of the water phase jet into particles, resulting in the conformal coating of the biomaterial, wherein the thickness of the conformal coating is not dependent on the size or diameter of the coated biomaterial, and wherein polymerization of the coating material occurs downstream of breakup of the water phase jet into particles;
c) optionally collecting the outflow of the coating device;
d) optionally purifying the conformally coated biomaterial and biomaterial-free coating material from the oil phase; and
e) optionally separating the conformally coated biomaterial from the biomaterial-free coating material,
wherein the conformal coating around the biomaterial ranges from 1-100 ?m in thickness;
wherein the biomaterial comprises islet cells and cell clusters; andwherein the water phase comprises about 75,000 islet cells/ml, and further comprises:a) about 10% polyethylene glycol (PEG), about 2% polyoxyethylene-polyoxypropylene block copolymer, and about 0.62% w/v dithiothreitol (DTT) in serum-free media at pH 6-7;
b) about 5% PEG, about 1% polyoxyethylene-polyoxypropylene block copolymer, and about 0.31% w/v DTT in Hank's Balanced Salt Solution (HBSS) at pH 6-7;
c) about 5% PEG, about 1% polyoxyethylene-polyoxypropylene block copolymer, about 0.8% medium viscosity G-groups alginate and about 0.31% w/v DTT in HBSS without Ca2+ and Mg2+ at pH 6-7; or
d) about 5% PEG, about 0.8% medium viscosity G-groups alginate and about 0.31% w/v DTT in HBSS without Ca2+ and Mg2+ at pH 6-7.
US Pat. No. 10,655,096

BIOMANUFACTURING SYSTEM, METHOD, AND 3D BIOPRINTING HARDWARE IN A REDUCED GRAVITY ENVIRONMENT

Techshot, Inc., Greenvil...

1. A method for the additive manufacturing of living tissue in a reduced gravity environment comprising:providing a reduced gravity environment;
providing a manufacturing facility for use in said reduced gravity environment, said manufacturing facility having a housing containing therein a bioprinter and a cell culturing bioreactor, wherein said cell culturing bioreactor defines an interior;
providing one or more bioinks in fluid communication with said bioprinter, wherein said cell culturing bioreactor is in fluid communication with said one or more bioinks from said bioprinter, wherein said one or more bioinks comprises one or more cells;
printing one or more three-dimensional tissues with said one or more bioinks from said bioprinter into said interior of said cell culturing bioreactor having no media therein within said reduced gravity environment;
supplying said interior of said cell culturing bioreactor containing said one or more three-dimensional tissues with liquid media; and
incubating said one or more three-dimensional tissues within said cell culturing bioreactor to promote at least one of cell proliferation, differentiation, and remodeling into a final product tissue.
US Pat. No. 10,654,843

LMP7 INHIBITORS

Principia Biopharma Inc.,...

1. A compound selected from the group consisting of:N-((2S,3R)-1-(((S)-6-(2-cyano-4-methylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-1-((4-methyl-benzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-4,4-dimethylpent-2-enamido)-1-((4-methyl-benzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-6-(2-cyano-4-methylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-6-(2-cyano-4,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((R)-1-(((S)-6-(2-cyano-4,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
(S)—N-(6-(2-cyano-4,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)pyrazine-2-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(3-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(3-((1-methyl-2,5-dioxopyrrolidin-3-ylidene)-methyl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-6-(2-cyano-N,4,4-trimethylpent-2-enamido)-1-((4-methylbenzyl)-amino)-1-oxohexan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(4-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)-phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-5-(2-cyano-4,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxopentan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-3-(3-(2-cyano-4,4-dimethylpent-2-enamido)phenyl)-1-((4-methyl-benzyl)amino)-1-oxopropan-2-yl)amino)-3-methoxy-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2 S, 3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(2-cyano-4-methylpent-2-enamido)phenyl)-1-((4-methyl-benzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-4-methylpent-2-enamido)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-5-(2-cyano-4-methylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxopentan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(4-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-4-(4-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-4-(4-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-1-(((S)-6-(2-cyano-4-methylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
(S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-(4-methyl-phenylsulfonamido)butanamido)-N-(4-methylbenzyl)hexanamide;
(S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-(4-methylphenyl-sulfonamido)butanamido)-N-(4-methylbenzyl)hexanamide;
N-((2S,3R)-1-(((S)-4-(4-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-4-(3-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
(S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-(2-morpholinoacetamido)butanamido)-N-(4-methylbenzyl)hexanamide;
(S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-2-((2S,3R)-2-(3-(3-fluorophenyl)-propanamido)-3-hydroxybutanamido)-N-(4-methylbenzyl)hexanamide;
(S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-(2-morpholino-acetamido)-butanamido)-N-(4-methylbenzyl)hexanamide;
(S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2S,3R)-2-(3-(3-fluorophenyl)-propanamido)-3-hydroxybutanamido)-N-(4-methylbenzyl)hexanamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-4-methyl-4-morpholinopent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
(S)—N-(1-((6-(2-cyano-N,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-N,4-dimethyl-4-morpholinopent-2-enamido)-1-((4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-4-(3-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-4-methylpent-2-enamido)-1-((2-fluoro-4-methyl-benzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-1-((2-chlorobenzyl)amino)-6-(2-cyano-N,4-dimethylpent-2-enamido)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((2S)-3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-3-yl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2 S, 3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2 S, 3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-chlorobenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-4-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenyl)-1-((2-chlorobenzyl)amino)-1-oxobutan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-(2-morpholinoacetamido)-butanamide;
N-((2 S, 3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-2-methylthiazole-5-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-isobutyramidobutanamide;
N-((2S,3R)-1-(((S)-1-((2-chloro-4-methylbenzyl)amino)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5 -methylisoxazole-3-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-2-(3-(3-fluorophenyl)propanamido)-3-hydroxybutanamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-2-(1H-1,2,4-triazol-1-yl)vinyl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methyl-isoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-1-((2-chlorobenzyl)amino)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-2-methyl-thiazole-5-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-isobutyramidobutanamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-2-((6-chloropyrazin-2-yl)amino)-3-hydroxybutanamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-((2,2,2-trifluoroethyl)amino)-butanamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
2-cyano-N-(3-((S)-2-((2S,3R)-2-(3-(3-fluorophenyl)propanamido)-3-hydroxy-butanamido)-3-((4-methylbenzyl)amino)-3-oxopropyl)phenyl)-N,4-dimethylpent-2-enamide;
(2S,3R)—N—((S)-3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-2-(3-(3-fluorophenyl)propanamido)-3-hydroxybutanamide;
(2S,3R)—N—((S)-1-((2-chlorobenzyl)amino)-3-(1-(2-cyano-4-methylpent-2-enoyl)-piperidin-4-yl)-1-oxopropan-2-yl)-2-(3-(3-fluorophenyl)propanamido)-3-hydroxybutanamide;
N-((2S,3R)-1-(((S)-3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3-methylisoxazole-5-carboxamide;
N-((2S,3R)-1-(((S)-1-((2-chlorobenzyl)amino)-3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3-methyl-isoxazole-5-carboxamide;
N—((S)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N—((S)-2-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-cyclopropyl-2-oxoethyl)-5-methylisoxazole-3-carboxamide;
N—((S)-2-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)-5-methylisoxazole-3-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-(phenylamino)butanamide;
(2S,3R)—N—((S)-3-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
N-(3-((S)-3-((2-chlorobenzyl)amino)-2-((2S,3R)-3-hydroxy-2-pivalamidobutanamido)-3-oxopropyl)phenyl)-2-cyano-N,4-dimethylpent-2-enamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
(2S,3R)—N—((S)-1-((2-fluoro-4-methylbenzyl)amino)-3-(3-((3-methyl-2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
2-cyano-N-(3-((S)-3-((2-fluoro-4-methylbenzyl)amino)-2-((2S,3R)-3-hydroxy-2-pivalamidobutanamido)-3-oxopropyl)phenyl)-N,4-dimethylpent-2-enamide;
(2S,3R)—N—((S)-3-(3-(2-cyano-2-(1H-1,2,4-triazol-1-yl)vinyl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
2-cyano-N-(3-((S)-3-((2-fluoro-4-methylbenzyl)amino)-2-((2S,3R)-2-(3-(3-fluorophenyl)propanamido)-3-hydroxybutanamido)-3-oxopropyl)phenyl)-N,4-dimethylpent-2-enamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-N-ethyl-4-methylpent-2-enamido)phenyl)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3-methylisoxazole-5-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-2-(1H-1,2,4-triazol-1-yl)vinyl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3 -methylisoxazole-5-carboxamide;
2-cyano-N-(2-((S)-3-((2-fluoro-4-methylbenzyl)amino)-2-((2S,3R)-3-hydroxy-2-pivalamidobutanamido)-3-oxopropoxy)ethyl)-N,4-dimethylpent-2-enamide;
N-((2S,3R)-1-(((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)oxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3-methylisoxazole-5-carboxamide;
N-((2S,3R)-1-(((S)-3-(((S)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)oxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-3-methylisoxazole-5-carboxamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-(4-methylphenylsulfonamido)-butanamide;
N-((2 S, 3R)-1-(((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((cyclohexylmethyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5 -methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(4-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-2-(1H-1,2,4-triazol-1-yl)vinyl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)oxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(((S)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-3-yl)oxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-3-hydroxy-1-(((S)-3-(3-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-3-(4-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)-phenoxy)-1-((4-methylbenzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
(2S,3R)—N—((S)-3-(3-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
(2S,3R)—N—((S)-3-(4-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-pivalamidobutanamide;
(2S,3R)—N—((S)-3-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-((2,2,2-trifluoroethyl)-amino)butanamide;
(2S,3R)—N—((S)-3-(3-(2-cyano-3-(dimethylamino)-3-oxoprop-1-en-1-yl)phenoxy)-1-((2-fluoro-4-methylbenzyl)amino)-1-oxopropan-2-yl)-3-hydroxy-2-isobutyramidobutanamide;
N-((2S,3R)-3-hydroxy-1-(((S)-4-(3-((3-methyl-2,4-dioxothiazolidin-5-ylidene)-methyl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-4-(3-(3-(tert-butylamino)-2-cyano-3-oxoprop-1-en-1-yl)phenyl)-1-((4-methylbenzyl)amino)-1-oxobutan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-4-methylpent-2-enamido)-1-((4-methylbenzyl)-amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
N-((2S,3R)-1-(((S)-1-(benzylamino)-6-(2-cyano-4-methylpent-2-enamido)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carb oxamide;
N-((2S,3R)-1-(((S)-6-(2-cyano-N,4-dimethylpent-2-enamido)-1-((4-methylbenzyl)-amino)-1-oxohexan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide; and,
N-((2S,3R)-1-(((S)-3-(3-(2-cyano-4-methylpent-2-enamido)phenyl)-1-((4-methyl-benzyl)amino)-1-oxopropan-2-yl)amino)-3-hydroxy-1-oxobutan-2-yl)-5-methylisoxazole-3-carboxamide;
an E or Z isomer thereof;
or, a pharmaceutically acceptable salt of any of the foregoing compounds.
US Pat. No. 10,655,099

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Baxalta Incorporated, Ba...

1. A method for cultivating cells, comprising the steps of:(a) providing an animal protein-free cell culture medium;
(b) adding a supplement to the animal protein-free cell culture medium comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast, wherein the resultant concentration of the at least one polyamine in the animal protein-free cell culture medium ranges from about 0.5 to about 30 mg/L; and
(c) propagating the cells in the animal protein-free cell culture medium to form a cell culture.
US Pat. No. 10,655,100

METHOD FOR INDUCING ECTODERMAL DIFFERENTIATION OF EMBRYOID BODIES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS BY CXCR2 STIMULATION

KOREA UNIVERSITY RESEARCH...

1. A method or inducing differentiation of human induced pluripotent stern (iPS) cells into ectoderm, the method comprising the steps of:(i) forming embryoid bodies from human induced pluripotent stem (iPS) cells; and
(ii) culturing the embryoid bodies in a medium comprising GRO-? for 14-20 days to induce differentiation into ectoderm by CXCR2 stimulation,
wherein the ectoderm expresses Nestin, Sox1, Pax6, and Prox1.
US Pat. No. 10,655,101

METHODS OF IN VITRO OOCYTE DEVELOPMENT

THE UNIVERSITY COURT OF T...

1. A method of preparing ovarian tissue for primordial follicle growth comprising the steps:providing an ovarian tissue sample comprising cortical tissue and stromal tissue;
removing damaged tissue from the ovarian tissue, sample where present;
removing excess stromal tissue from the ovarian tissue sample where present; and then
mechanically stretching the ovarian tissue sample along at least one dimension of the ovarian tissue sample, such that the size of the ovarian tissue sample along the at least one dimension is increased by at least 10%.
US Pat. No. 10,653,822

DRUG DELIVERY DEVICES AND METHODS OF MAKING AND USING SAME

THE ADMINSTRATORS OF THE ...

1. A drug delivery device, consisting of a multi-layer film, wherein the multi-layer film comprises at least a first layer comprising a first anti-fibrotic drug associated with a first biodegradable polymer film; and, at least a second layer comprising a second anti-fibrotic drug associated with a second biodegradable polymer film, wherein the first layer of the drug delivery system is configured to provide a sustained release of the first anti-fibrotic drug and the second layer of the drug delivery system is configured to provide a burst release of the second anti-fibrotic drug on contact with the aqueous humor, where the first biodegradable polymer film and the second biodegradable polymer film comprise a poly lactic-co-glycolic acid (“PLGA”), and at least the first biodegradable polymer film further comprises a polyethyleneglycol (“PEG”) in a ratio of about 1:9 of PLGA:PEG.
US Pat. No. 10,654,078

METHOD OF REMOVING AN UNWANTED CONSTITUENT FROM A SURFACE, A METHOD OF DETERMINING THE CLEANLINESS OF A HARD SURFACE, AND A MULTI-FUNCTIONAL COMPOSITION THAT INCLUDES HYDROPHILIC SILANE

3M INNOVATIVE PROPERTIES ...

1. A multi-functional solution comprising:a first hydrophilic zwitterionic silane;
a first surfactant;
the ratio of the weight of the first hydrophilic zwitterionic silane to the weight of the first surfactant being at least 1:1, such that the amount of the first surfactant is equal to or greater than the amount of the first hydrophilic zwitterionic silane; and
water.
US Pat. No. 10,655,103

EQUINE PROGENITOR CELLS

UNIVERSITY COLLEGE CARDIF...

1. A method of treating damaged cartilage in a horse, the method comprising:administering an isolated equine articular cartilage progenitor cell (ACPC) to damaged cartilage tissue in a horse such that cartilage is produced and the damaged cartilage tissue is functionally repaired, wherein said ACPC:
a) is the equine progenitor cell population deposited under Accession No. 09101301 at the European Collection of Cell Cultures (ECACC);
b) has a population doubling at a rate of approximately one population per day;
c) has the ability to differentiate into chondrogenic, osteogenic, and adipogenic lineages; and
d) expresses Type I and Type II collagen but not Type X collagen following chondrogenic differentiation.
US Pat. No. 10,653,825

METHOD FOR PRIMING HOLLOW-FIBER MEMBRANE MODULE

KANEKA CORPORATION, Osak...

1. A method for priming a hollow-fiber membrane module in which hollow-fiber membranes are packed in a vessel having an inlet port, an outlet port, and a filtrate discharge port, comprising:filling a priming liquid in the hollow-fiber membrane module in an amount of 15% or more relative to a volume of the hollow-fiber membrane module at a linear velocity of 35 cm/min or more and 300 cm/min or less from the inlet port or the outlet port of the hollow-fiber membrane module;
wherein the inlet port and the outlet port communicate with each other through the inside of the hollow fiber membrane while maintaining a closed environment in the hollow-fiber membrane module.
US Pat. No. 10,655,105

METHOD FOR PROLIFERATION OF PANCREATIC PROGENITOR CELLS

Takeda Pharmaceutical Com...

1. A method for proliferation of pancreatic progenitor cells, comprising:culturing the pancreatic progenitor cells in a medium comprising (i) an EGF signal transduction activator and/or an FGF signal transduction activator, and (ii) a Wnt signal inhibitor, wherein the Wnt signal inhibitor is selected from the group consisting of IWP2, IWP3, IWP4, 2-(4-trifluoromethylphenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4(3H)-one (XAV939), IWR1, G-CSF, IGFBP4, Dkk1, and Frzb-1.
US Pat. No. 10,655,107

ADHERENT CELL CULTURE METHOD

Corning Incorporated, Co...

1. A method of culturing adherent cells, the method comprisingseeding adherent cells by injecting a culture medium containing the adherent cells into each culture space of a plurality of culture spaces within a culture chamber,
culturing the adherent cells to form spheroids of the adherent cells in each culture space,
culturing the spheroid within each culture space,
wherein:
each culture space has an equivalent diameter that is 1 to 3 times the diameter of a desired spheroid and said equivalent diameter is within the range of 100 ?m to 200 ?m;
each culture space has a height that is 0.5 to 2 times the equivalent diameter;
a surface of each culture space has a water contact angle of 45 degrees or less;
each culture space has either a cylindrical shape or a rectangular prism shape, and a flat culture bottom surface;
each culture space comprises a wall partitioning the adjacent culture spaces;
the culture space wall has a height equal to the height of the culture space, and a thickness in the range of 5 ?m to 50 ?m;
the spheroid cultured in each culture space is contained within the culture space, and does not come into contact with the spheroid in an adjacent culture space during the culturing; and
60% or more of all cultured spheroids have a diameter within a range of 5% below to 5% above an average value of diameters of the spheroids obtained after the culturing.
US Pat. No. 10,655,109

RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STAINS WITH MUTATIONS IN THE M2-2 ORF PROVIDING A RANGE OF ATTENUATION PHENOTYPES

The United States of Amer...

1. A recombinant respiratory syncytial virus (RSV) attenuated by one or more modifications to a recombinant RSV genome, wherein the one or more modifications comprise:(a) a deletion in a M2-2 open reading frame (ORF) corresponding to a deletion of 241 nucleotides at positions 8189-8429 of SEQ ID NO: 1, combined with nucleotide mutations at positions corresponding to T8161, T8167 and T8179 of SEQ ID NO: 1 (“?M2-2”);
(b) a deletion in a M2-2 ORF corresponding to a deletion of 234 nucleotides at positions 8203-8436 of SEQ ID NO: 1, combined with nucleotide mutations at positions corresponding to 8198A and 8200G of SEQ ID NO: 1 (“?M2-2-AclI”); or
(c) a deletion in a M2-2 ORF corresponding to a deletion of 234 nucleotides at positions 8203-8436 of SEQ ID NO: 1, combined with nucleotide mutations at positions corresponding to 8198A and 8199G of SEQ ID NO: 1 (“?M2-2-HindIII”), wherein the recombinant RSV genome is a D46 genome attenuated by the one or more modifications.
US Pat. No. 10,654,854

SALTS AND CRYSTALS OF ITI-007

INTRA-CELLULAR THERAPIES,...

1. A salt of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007), wherein the salt is selected from the oxalate, the 4-aminosalicylate, and the cyclamate, and wherein the salt is in crystalline form.
US Pat. No. 10,655,110

MULTIVALENT DENGUE VACCINE COMPOSITION COMPRISING A MIXTURE OF ATTENUATED DENGUE VIRUSES FROM DIFFERENT SEROTYPES

KM BIOLOGICS CO., LTD., ...

1. An attenuated dengue virus (DENV) vaccine composition comprising one or more non-naturally-occurring attenuated DENVs selected from the group consisting of a mixture of attenuated serotype 1 dengue viruses (DENV1), a mixture of attenuated serotype 2 dengue viruses (DENV2), a mixture of attenuated serotype 3 dengue viruses (DENV3), and a mixture of attenuated serotype 4 dengue viruses (DENV4), wherein said vaccine has the following features:(a) said attenuated DENV1 mixture comprises DENV1 viruses with the following mutations: K482E/K, E483K, K484R/K, K568R, N1663K, I/T2353T, and A2364T/A;
wherein said numbering is based upon the DENV1 parent strain 03135 comprising SEQ ID NO:1;
(b) said attenuated DENV2 mixture comprises DENV2 viruses with the following mutations: D143N, T400K, D1102N, L1308F, E1654K, P2347P/L and T2828T/M;
wherein said numbering is based upon the DENV2 parent strain 99345 comprising SEQ ID NO:2;
(c) said attenuated DENV3 mixture comprises DENV3 viruses with the following mutations: I209L, S582G, K/R671K, A687V, T764I/T, F1211L, A1237T, and Q1563K;
wherein said numbering is based upon the DENV3 parent strain 16562 comprising SEQ ID NO:3; and,
(d) said attenuated DENV4 mixture comprises DENV4 viruses with the following mutations: L2187F and F/L2354S,
wherein said numbering is based upon the DENV4 parent strain 1036 comprising SEQ ID NO:4.
US Pat. No. 10,658,696

NONAQUEOUS SECONDARY BATTERY

NISSAN CHEMICAL INDUSTRIE...

1. A nonaqueous secondary cell comprising:a positive electrode having a positive electrode current-collecting substrate, an electrically conductive protective layer formed on the surface of the positive electrode current-collecting substrate and a positive electrode active material layer capable of intercalating and deintercalating lithium formed on the surface of the electrically conductive protective layer;
a negative electrode having a negative electrode current-collecting substrate and, formed on top thereof, a negative electrode active material layer capable of intercalating and deintercalating lithium;
a separator interposed between the positive and electrode electrodes; and
a nonaqueous electrolyte solution, wherein
the nonaqueous electrolyte solution comprises a sulfonylimide electrolyte and a nonaqueous organic solvent,
the electrically conductive protective layer an electrically conductive carbon material dispersed in a binder resin, and
the conductive carbon material is at least one selected from the group consisting of fibrous conductive carbon materials and particulate conductive carbon materials.
US Pat. No. 10,655,111

MODULATION OF LIPID METABOLISM FOR PROTEIN PRODUCTION

LONZA LTD., Visp (CH)

1. A cell comprising:a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM), wherein the first LMM comprises a sterol regulatory element-binding transcription factor 1 (SREBF1) or a functional fragment or isoform thereof; and
an exogenous nucleic acid encoding a recombinant polypeptide,
wherein the first exogenous nucleic acid is integrated into the chromosomal genome of the cell; and
wherein the cell is a CHO-derived cell.
US Pat. No. 10,655,112

POLYPEPTIDE HAVING ENDONUCLEASE ACTIVITY AND METHOD FOR PRODUCING THE SAME

KANEKA CORPORATION, Osak...

1. A polypeptide comprisingan amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1 and
derived from the amino acid sequence of SEQ ID NO: 1 by substitution, deletion, and/or addition of one or more amino acid residues,
wherein a yeast host expressing the polypeptide in a secretory production system does not add an N-linked sugar chain to the polypeptide,
wherein the polypeptide has endonuclease activity,
wherein the polypeptide comprises at least one of:
an amino acid residue selected from the group consisting of glycine, proline, aspartic acid, glutamic acid, threonine, alanine, valine, histidine, arginine, methionine, isoleucine, leucine, cysteine, tyrosine, phenylalanine, glutamine, tryptophan, serine, and lysine at a position corresponding to N20 of SEQ ID NO: 1;
proline at a position corresponding to V21 of SEQ ID NO: 1; or
an amino acid residue selected from the group consisting of valine, alanine, and lysine at a position corresponding to S22 of SEQ ID NO: 1, and
wherein the polypeptide further comprises at least one of:
an amino acid residue selected from the group consisting of glutamine, tyrosine, and alanine at a position corresponding to N33 of SEQ ID NO: 1;
proline at a position corresponding to S34 of SEQ ID NO: 1; or
an amino acid residue selected from the group consisting of lysine, valine, arginine, leucine, glycine, glutamine, phenylalanine, tryptophan, asparagine, isoleucine, glutamic acid, alanine, histidine, methionine, aspartic acid, cysteine, proline, and tyrosine at a position corresponding to T35 of SEQ ID NO: 1.
US Pat. No. 10,658,698

PEO-BASED GRAFT COPOLYMERS WITH PENDANT FLUORINATED GROUPS FOR USE AS ELECTROLYTES

SEEO, INC., Hayward, CA ...

20. A block copolymer electrolyte comprising:a block copolymer comprising:
a first block which is a graft copolymer comprising a plurality of PEO molecules and perfluoro functional groups grafted onto at least a portion of the plurality of PEO molecules, the perfluoro functional groups have a molecular weight ranging from 200 to 10,000 Da; and
a second block comprising a polymer that has a modulus in excess of 1×105 Pa at temperatures at and below 25° C.; and
a metal salt.
US Pat. No. 10,655,113

METHODS OF GENERATING AND SCREENING FOR LYTIC CHIMERIC POLYPEPTIDES

HYPHARM GMBH, Bernried (...

1. A method of generating a chimeric polypeptide having at least one cell binding domain (CBD) and at least one enzymatic active domain (EAD), the method comprising the steps of:(a) providing one or more DNA sequences each encoding at least one CBD and one or more DNA sequences each encoding at least one EAD, and optionally one or more DNA sequences each encoding at least one CBD and at least one EAD, wherein the EAD is selected from the group consisting of
(i) the lytic domain of a bacteriophage lysin; and
(ii) a bacteriophage tail-associated protein having lytic activity;
(b) amplifying a first (1st) domain sequence selected from the domain sequences of (a) using a pair of primers designed to introduce different restriction sites at the 5?-end and at the 3?-end, and a tag labeling at the 5?-end or at the 3?-end;
(c) amplifying a second (2nd) domain sequence selected from the domain sequences of (a) using a pair of primers designed to introduce:
(i) in case of 5?-end labelling of the 1st domain: at the 5?-end the same restriction site as at the 3?-end of the first domain, and at the 3?-end a restriction site different from the restriction sites introduced into the 1st domain sequence,
(ii) in case of 3?-end labelling of the 1st domain: at the 3?-end the same restriction site as at the 5?-end of the 1st domain, and at the 5?-end a restriction site different from the restriction sites introduced into the 1st domain sequence;
(d) amplifying a third (3rd) domain sequence selected from the domain sequences of (a) using a pair of primers designed to introduce:
(i) in case of 5?-end labelling of the 1st domain: at the 5?-end the same restriction site as at the 3?-end of the preceding 2nd domain, and at the 3?-end a restriction site that is different from that at the 5?-end of the 1st domain,
(ii) in case of 3?-end labelling of the 1st domain: at the 3?-end the same restriction site as at the 5?-end of the preceding 2nd domain, and at the 5?-end a restriction site that is different from that at the 3?-end of the 1st domain;
wherein the pair of primers is further designed such that the restriction sites are different at the 5?-end and the 3?-end of the 3rd domain sequence;
(e) optionally amplifying one or more further domain sequences selected from the domain sequences of (a) for extending the series of domain sequences according to steps (b) to (d), using for each of said one or more further domain sequences a pair of primers designed following the principle of steps (c) and (d) so as to introduce:
(i) in case of 5?-end labelling of the 1st domain: at the 5?-end the same restriction site as at the 3?-end of the preceding domain, and at the 3?-end a restriction site that is different from that at the 5?-end of the 1st domain,
(ii) in case of 3?-end labelling of the 1st domain: at the 3?-end the same restriction site as at the 5?-end of the preceding domain, and at the 5?-end a restriction site that is different from that at the 3?-end of the 1st domain;
wherein the pair of primers is further designed such that the restriction sites are different at the 5?-end and the 3?-end of each of said one or more further domain sequences;
(f) performing a restriction digest of the amplified domain sequences of any of steps (b) to (e) using restriction enzymes targeting the restriction sites introduced in any of steps (b) to (e), wherein a restriction digest is not performed on the restriction site introduced to an end carrying a tag labelling;
(g) ligating the digested 1st and 2nd domain sequence obtained in step (f) to obtain a ligation product comprising the 1st and 2nd domain sequence;
(h) binding the ligation products of step (g) to a solid support using the tag labeling of the 1st domain sequence to obtain a bound ligation product comprising the 1st and 2nd domain sequence;
(j) optionally ligating the digested 3rd domain sequence of (d) obtained in step (f) to the bound ligation product of step (h) to obtain a bound ligation product comprising the 1st, 2nd and 3rd domain sequence;
(k) optionally ligating one or more digested domain sequences of (e) obtained in step (f) to the bound ligation product of step (j) to obtain a bound ligation product comprising one or more further domain sequences of (e);
(l) releasing the ligation product obtained in any one of steps (h) to (k) from the solid support; and
(m) characterizing the ligation product obtained in step (l) and identifying chimeric polypeptides having at least one CBD and at least one EAD.
US Pat. No. 10,655,114

ENGINEERED ENZYMES

Inscripta, Inc., Boulder...

1. An engineered nucleic acid-guided nuclease having editing activity in yeast different than the nucleic acid-guided nuclease having the sequence of SEQ ID No. 1, wherein the engineered nucleic acid-guided nuclease has a sequence comprising any of SEQ ID Nos. 69-78 or 79-86.
US Pat. No. 10,655,115

CARBOHYDRATE DEGRADING POLYPEPTIDE AND USES THEREOF

DSM IP ASSETS B.V., Heer...

1. A polypeptide having hemicellulase activity, comprising:(i) an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 72 and containing at least one substitution modification relative to said sequence; or
(ii) an amino acid sequence containing at least one substitution modification relative to SEQ ID NO: 72, encoded by a nucleic acid sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 71, 74 and 75.
US Pat. No. 10,657,933

ALGORITHMIC METHOD FOR SPELLING THE PITCHES OF ANY MUSICAL SCALE

DOKUZ EYLUL UNIVERSITESI ...

1. A method for spelling pitches of any musical scale, comprising:in a first stage, searching a path using a maximum number of different columns of a matrix;
in a second stage, searching a path including a minimum number of augmented or diminished musical intervals by choosing a path or a plurality of paths having a lowest score after calculating a penalty score by finding extreme intervals through an investigation of an interval type between each two elements of each path;
in a third stage, determining a preference of the path or the plurality of paths including a representation of a maximum number of natural pitches;
in a fourth stage, determining a preference of the path or the plurality of paths including a minimum number of double flats and double sharps; and
in a fifth stage, checking whether, or not, paths having pitches with a sharp sign between two naturals exist, wherein the two naturals are two semitones apart from each other.
US Pat. No. 10,655,116

VARIANTS AND COMPOSITIONS COMPRISING VARIANTS WITH HIGH STABILITY IN PRESENCE OF A CHELATING AGENT

1. A variant of a parent alpha-amylase comprising at least two-deletions in amino acid positions 181, 182, 183, or 184 and further comprising a substitution at amino acid positions 206 and 458, wherein:(a) the variant has alpha-amylase activity; and
(b) each amino acid position corresponds to a position set forth in SEQ ID NO: 6.
US Pat. No. 10,655,117

PULLULANASE AND USE THEREOF

BEIJING HONGMING XINDA TE...

1. A pullulanase mutant having pullulanase activity, wherein, the said pullulanase mutant comprises the amino acid sequence of SEQ ID NO.4.
US Pat. No. 10,656,141

SELECTION OF AGENTS MODULATING GASTROINTESTINAL PAIN

BIOGAIA AB, Stockholm (S...

1. A method for selecting a lactic acid bacterial strain for reducing gastrointestinal pain locally in a subject, said method comprising:contacting a cell expressing transient receptor potential vanilloid 1 (TRPV1) with the bacterial strain;
measuring spontaneous and/or induced TRPV1 activation in said cell following the contacting; and
selecting said bacterial strain effective in reducing gastrointestinal pain locally when said measured spontaneous and/or induced TRPV1 activation is lower than control TRPV1 activation.
US Pat. No. 10,658,191

CONFORMAL MIDDLE LAYER FOR A LITHOGRAPHY PROCESS

TAIWAN SEMICONDUCTOR MANU...

1. A method comprising:depositing a bottom layer of a tri-layer resist on a substrate, the substrate having variations in height such that a top surface of the bottom layer has a cupping shape;
performing a first polymerization process on a solution of monomers to form a partially processed resin solution, the partially processed resin solution comprising a solvent, the monomers, and a silicon-based resin;
after the performing of the first polymerization process, spin coating the partially processed resin solution on the bottom layer of the tri-layer resist to form a middle layer of the tri-layer resist;
performing a second polymerization process on the partially processed resin solution spin-coated on the substrate to shrink the partially processed resin solution spin-coated on the substrate to form a conformal silicon-based resin layer that conforms to the cupping shape of the top surface of the bottom layer; and
forming a patterned photoresist layer as a top-layer of the tri-layer resist directly on the middle layer of the tri-layer resist.
US Pat. No. 10,658,703

NEGATIVE ELECTRODE PLATE AND SECONDARY BATTERY COMPRISING THE SAME

Contemporary Amperex Tech...

1. A secondary battery, comprising a negative electrode plate, the negative electrode plate comprising a negative electrode current collector and a negative electrode layer coated on at least one surface of the negative electrode current collector, the negative electrode layer comprising a negative electrode active material, wherein the negative electrode active material comprises a graphite material, and the negative electrode plate fulfills the condition:0.2?4×L×VOI?¼×Dn10?25  formula I)
and the negative electrode layer has a VOI value of 11.7?VOI?68.3;
and the negative electrode active material has a Dn10 value of Dn10?6;
wherein
L represents the thickness of single-side negative electrode layer on the negative electrode current collector in millimeter,
Dn10 represents the particle diameter that corresponds to 10% of the number distribution of particles of the negative electrode active material in micrometer,
VOI represents the OI value of the negative electrode layer.
US Pat. No. 10,655,118

HEAT-RESISTANT AGARASE AND MONOSACCHARIDE PRODUCTION METHOD USING SAME

Korea University Research...

1. A method for producing galactose or 3,6-anhydro-L-galactose, comprisingreacting an agarase comprising the amino acid sequence of SEQ ID NO: 1 with not-pretreated agarose or agar as a substrate under a temperature range of 50 to 60° C. to produce neoagarotetraose or neoagarohexaose as a reaction product,
reacting an agarase comprising the amino acid sequence of SEQ ID NO: 3 with the reaction product to produce neoagarobiose, and
reacting an ?-neoagarobiose hydrolase comprising the amino acid sequence of SEQ ID NO: 4 with neoagarobiose to produce galactose or 3,6-anhydro-L-galactose.
US Pat. No. 10,656,142

MEASURING ANTIPLATELET ACTIVITY

Melaleuca, Inc., Idaho F...

1. A method for determining the presence or absence of antiplatelet activity for a substance, said method comprising:a) determining the rate of superoxide radical formation in a first blood sample obtained from a subject before administration of a substance to the subject, wherein determining said rate of superoxide radical formation comprises:
1) applying oscillatory shear stress to said first sample, wherein said oscillatory shear stress is applied at physiological pO2 concentration;
2) dividing said first sample into two or more aliquots; and
3) measuring the amount of superoxide radical in each aliquot of said first sample over a first period of time to determine the rate of superoxide radical formation in said first sample, wherein the amount of superoxide radical is measured by an Electron Paramagnetic Resonance (EPR) method;
b) determining the rate of superoxide radical formation in a second blood sample obtained from a subject after administration of a substance to the subject, wherein determining said rate of superoxide radical formation comprises:
1) applying oscillatory shear stress to said second sample, wherein said oscillatory shear stress is applied at physiological pO2 concentration; and
2) dividing said second sample into two or more aliquots; and
3) measuring the amount of superoxide radical in each aliquot of said second sample over a second period of time to determine the rate of superoxide radical formation in said second sample, wherein the amount of superoxide radical is measured by an EPR method; and
c) comparing the rate of superoxide radical formation in said samples, wherein a lower rate of superoxide radical formation in said second sample indicates the presence of antiplatelet activity of said substance;
wherein said rate of superoxide radical formation in said second sample was measured at from 1 hour to about 24 hours following administration of said substance; and wherein said administration of said substance comprises a single dose of said substance.
US Pat. No. 10,654,863

BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF

KemPharm, Inc., Celebrat...

1. A method of treating a patient having acute pain, comprising orally administering to the patient a pharmaceutically effective amount of a composition comprising benzhydrocodone and acetaminophen in an amount of 6.12 mg benzhydrocodone and 325 mg acetaminophen.
US Pat. No. 10,655,119

MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA

INSERM (INSTITUT NATIONAL...

1. A mammalian mutated factor X polypeptide, having the amino acid sequence set forth in SEQ ID NO: 1, which comprises a heavy chain, wherein at least one amino acid residue at position 441 and/or position 448 is mutated, and wherein said factor X polypeptide is not inactivated by a factor X inhibitor selected from the group consisting of antithrombin (AT), tissue pathway inhibitor (TFPI) and alloantibodies to factor X.
US Pat. No. 10,656,143

METHODS AND APPARATUSES FOR IDENTIFYING RED BLOOD CELLS INFECTED BY PLASMODIUM

SHENZHEN MINDRAY BIO-MEDI...

1. A method for identifying red blood cells infected by plasmodium while classifying white blood cells in a blood sample, said method comprising:treating the blood sample with a reagent comprising a hemolytic agent for lysing normal red blood cells, wherein the normal red blood cells are lysed into erythrocyte ghosts;
transmitting light into the blood sample;
detecting from within the blood sample a forward-scattered light intensity, a side-scattered light intensity and a fluorescence intensity from cells in the blood sample;
obtaining a three-dimensional scattergram generated from a combination of the forward-scattered light intensity, the side-scattered light intensity and the fluorescence intensity;
identifying cells located in a defined area of the three-dimensional scattergram as the red blood cells infected by plasmodium, wherein the cells located in the defined area are separated from an area where the erythrocyte ghosts are located, and wherein the defined area is determined according to a location of normal white blood cells and a function describing the relative location between an area of normal white blood cells and an area of red blood cells infected by plasmodium;
counting the number of the red blood cells infected by plasmodium in the defined area;
obtaining a blood routine examination parameter of erythrocytic series which correlates with plasmodium of the blood sample; and
giving a warning signal when the number of the red blood cells infected by plasmodium is more than a first threshold value or when the number of the red blood cells infected by plasmodium is less than the first threshold value and more than a second threshold value, and the blood routine examination parameter of erythrocytic series is out of a normal range.
US Pat. No. 10,655,120

TRANSPORT OF CELLS IN HYDROGELS

The University of Newcast...

1. A packaged composition comprising:(a) a 0.5%-1.3% calcium or strontium alginate hydrogel in the form of a thin layer or disc, wherein the hydrogel comprises pores of 0.1-3.0 ?m in diameter;
(b) a population of living cells, the living cells being entrapped or encapsulated within the hydrogel; and
(c) a packaging, the packaging being a water-tight or air-tight material suitable for transportation from a first location to a second location, wherein the second location is at least one mile from the first location, and the hydrogel is enclosed within the packaging;
wherein the hydrogel and the living cells entrapped or encapsulated therein are in a state of storage in the packaging from 1 day up to 20 weeks;
wherein cell division, and optionally cell differentiation, of all or a substantial proportion of the living cells which are entrapped or encapsulated within the hydrogel is suppressed or prevented.
US Pat. No. 10,656,144

IMMUNE PROFILING AND MINIMAL RESIDUE DISEASE FOLLOWING STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

The Charlotte Mecklenburg...

1. A method of treating a multiple myeloma (MM) patient, comprising:(a) establishing a peripheral immune profile of the MM patient by the steps of:
i) obtaining a biological sample from the MM patient;
ii) analyzing natural killer (NK), NK-T and T cell peripheral populations and/or activation in the biological sample;
iii) analyzing natural killer group (NKG) 2D (NKG2D) expression in NK and NK-T cells in the biological sample;
iv) analyzing killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1) expression in NK and T cells in the biological sample;
v) analyzing NKG2A expression in NK, NK-T and T cells in the biological sample;
vi) analyzing T-cell immunoglobulin and mucin-domain containing-3 (Tim3) expression in NK-T cells in the biological sample; and
vii) quantifying interleukin (IL)-12p70 (IL-12p70) and IL-17 pro-inflammatory cytokines and/or quantifying fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) pro-angiogenic growth factors in the biological sample;
b) comparing the peripheral immune profile of (a) to a pre-determined threshold, wherein the pre-determined threshold is established from peripheral immune profiles from a known population of minimal residue disease positive (MRDpos) and minimal residue disease negative (MRDneg) patients, wherein if the peripheral immune profile of (a) exceeds the pre-determined threshold, the MM patient is positive for MRD and if the peripheral immune profile of (a) is equal to or does not exceed the pre-determined threshold, the MM patient is negative for MRD; and
c) treating the patient having a peripheral immune profile that exceeds the pre-determined threshold, wherein the treatment is selected from steroids, stem cell transplantation, autologous stem cell transplantation (ASCT), induction therapy, thalidomide, lenalidomide, pomalidomide, proteasome inhibitor treatment, bortezomib-dexamethasone (VD), bortezomib-cyclophosphamide-dexamethasone with daratumumab (CyBorD-Dara), bortezomib-cyclophosphamide-dexamethasone without daratumumab (CyBorD), carfilzomib-cytoxan-dexamethasone (Car-Cy-Dex), bortezomib-melphalan-prednisone with daratumumab (VMP-Dara), bortezomib-melphalan-prednisone without daratumumab (VMP), bortezomib-dexamethasone-cisplatin-Adriamycin-cyclophosphamide-etoposide (VD-PACE), combination Daratumumab/Pembrolizumab, and any combination thereof.
US Pat. No. 10,656,145

DETECTION OF ALLERGENS USING SURFACE-ENHANCED RAMAN SCATTERING

General Mills, Inc., Min...

1. A method of detecting allergens using surface-enhanced Raman scattering (SERS) comprising:adding multiple groups of antibody-functionalized magnetic particles to a sample of a human-consumable product or ingredient thereof, wherein each group of the multiple groups of antibody-functionalized magnetic particles comprises an antibody selected to bind to an antigen corresponding to an allergen, and different groups of the multiple groups of antibody-functionalized magnetic particles have different antibodies selected to bind to different antigens corresponding to different allergens;
adding multiple groups of SERS tags complexed with antibodies to the sample, wherein each group of the multiple groups of SERS tags comprises an antibody selected to bind to the antigen corresponding to the allergen, and different groups of the multiple groups of SERS tags have different antibodies selected to bind to the different antigens corresponding to the different allergens, and wherein the SERS tag for each of the multiple groups of SERS tags are selected so different allergens exhibit different Raman spectrum shifts;
concentrating the multiple groups of antibody-functionalized magnetic particles in the sample, including any antigens and SERS tags bound thereto, by application of a magnetic field, thereby producing a concentrated sample, wherein concentrating the multiple groups of antibody-functionalized magnetic particles in the sample comprises attracting the multiple groups of antibody-functionalized magnetic particles to a magnetic field source and separating residual liquid not attracted to the magnetic field source from the multiple groups of antibody-functionalized magnetic particles attracted to the magnetic field source;
analyzing the concentrated sample with SERS, thereby producing a Raman spectrum; and
determining a concentration of each of the different allergens in the sample based on the Raman spectrum.
US Pat. No. 10,653,586

CURABLE COMPOSITION, CURABLE COMPOSITION FOR DENTAL USE, AND ORGANIC-INORGANIC COMPOSITE PARTICLES FOR DENTAL USE

TOKUYAMA DENTAL COOPERATI...

1. A curable composition, comprising:organic-inorganic composite particles, each of the organic-inorganic composite particles including an organic resin and inorganic particles;
a first polymerizable monomer;
a polymerization initiator; and
inorganic particles,
wherein a cured body formed by curing the curable composition includes:
a matrix formed by curing all constituent components of the curable composition except for the organic-inorganic composite particles; and
the organic-inorganic composite particles dispersed and contained in the cured body,
wherein an elastic modulus M of the matrix is larger than an elastic modulus P of the organic-inorganic composite particles by 3.0 GPa or more,
wherein the organic resin comprises a cured body of a second polymerizable monomer having a molecular weight per polymerizable functional group contained in a molecule that is in the range of 230 to 1000, and
wherein a molecular weight per polymerizable functional group contained in the first polymerizable monomer is in the range of 100 to 210.
US Pat. No. 10,655,122

METHOD, LYSIS SOLUTION AND KIT FOR SELECTIVELY DEPLETING ANIMAL NUCLEIC ACIDS IN A SAMPLE

QIAGEN GMBH, Hilden (DE)...

1. A method for selectively depleting animal nucleic acids from non-animal nucleic acids in a sample, the sample comprising animal cells and at least one further type of cells selected from microbial cells and plant cells or a combination thereof, the method comprising the steps of:i) selectively lysing the animal cells by contacting the sample with a lysis solution to obtain a mixture comprising intact microbial cells and/or plant cells as well as the animal nucleic acids released from the lysed animal cells into solution, said lysis solution being essentially chaotrope-free and comprising 0.01 to 15% (w/v) of a non-ionic surfactant, a water soluble salt selected from the group consisting of acetate, sulfate, glutamate, and mixtures thereof, and a sugar as a viscosity modifier,
ii) digesting both DNA and RNA of the animal nucleic acids in the presence of the intact microbial and/or plant cells, and
iii) separating the microbial and/or plant cells from the liquid part of the sample, including the digested animal nucleic acids.
US Pat. No. 10,658,196

CHEMICAL MECHANICAL POLISHING SLURRY COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR USING THE SAME

1. A chemical-mechanical polishing slurry composition, comprising:a polishing agent, an amine-based polishing activator, and a roughness adjusting agent,
wherein the amine-based polishing activator is a tertiary or quaternary amine, and
the roughness adjusting agent is a disaccharide, wherein the amine-based polishing activator is any one selected from the group consisting of tetraethylethylenediamine, tetrahydroxy ethylethylenediamine, and a combination thereof,
wherein the disaccharide is any one selected from the group consisting of lactose, maltose, turanose, and a combination thereof,
wherein the pH of the composition is adjusted to be 3 to 4.
US Pat. No. 10,655,123

GENOMIC SEQUENCE MODIFICATION METHOD FOR SPECIFICALLY CONVERTING NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE, AND MOLECULAR COMPLEX FOR USE IN SAME

National University Corpo...

1. A method of introducing a mutation into a desired nucleotide in a targeted site of a double stranded DNA, comprising:(a) selecting, in a targeted site of a double stranded DNA comprising a first DNA strand and a second DNA strand, a target nucleotide sequence in said second DNA strand that contains the desired nucleotide into which the mutation is to be introduced, and
(b) contacting said double stranded DNA with a complex that comprises
(i) a CRISPR-Cas system which comprises
(1) a Cas9 D10A mutant nickase protein (nCas9(D10A)) and
(2) a guide RNA that comprises a nucleotide sequence complementary to the first DNA strand, wherein the CRISPR-Cas system specifically binds to the selected target nucleotide sequence of (a) in the targeted site of the double stranded DNA, and
(ii) a nucleic acid base converting enzyme that is a deaminase linked to said nCas9(D10A) of (i),under conditions and for a time sufficient to introduce the mutation by converting the desired nucleotide in the targeted site to a different nucleotide or by deleting the desired nucleotide in the targeted site, wherein the nCas9(D10A) cleaves the first DNA strand without cleaving the second DNA strand of said double stranded DNA, wherein the desired nucleotide in the targeted site into which the mutation is introduced is positioned 2-5 nucleotides from the 5?-end of the target nucleotide sequence.
US Pat. No. 10,653,589

PERSONAL CARE COMPOSITION

Conopco, Inc., Englewood...

1. A personal care composition comprising:a) turbostratic boron nitride particles;
b) non-silicone polyolefin particles having an average particle size in the range of 0.5 to 5 microns; and
c) a cosmetically acceptable carrier.
US Pat. No. 10,655,125

POLYPEPTIDE LIBRARY

MOR0059US.NP, Planegg (D...


wherein
X1 is D, T, N, S or P,
X2 is E, P, Q, W or D,
X3 is M, A, I, Q or R,
X4 is A, L, R, M, K or E,
X5 is M, L, A, W, F or K,
Hy is any amino-acid residue having a side chain exhibiting a hydrophobicity of greater than 0.62, and
Var1, Var2 and Var3 are mixtures of the natural occurring amino acids, excluding G, P and C,
Li is a linker, and
said first and said second ?-helical peptide form an anti-parallel, coiled-coil structure.
US Pat. No. 10,656,149

ANALYTE DETECTION ENHANCEMENT BY TARGETED IMMOBILIZATION, SURFACE AMPLIFICATION, AND PIXELATED READING AND ANALYSIS

THE TRUSTEES OF PRINCETON...

1. A method of sample analysis, comprising:(a) binding target analytes to capture agents that are attached to a surface of a plate, wherein the plate comprises (i) a sensing amplification layer comprising nanostructures that enhance signals and (ii) the capture agents, wherein the capture agents are attached to said sensing amplification layer;
(b) reading the plate with a reading device to produce an image of signals that represent individual binding events, wherein the reading is done at a resolution sufficient to distinguish between individual binding events and the image shows bright spots that are spatially separated from one another that correspond to individual binding events between a single molecule of target analyte and a single molecule of capture agent;
(c) identifying the bright spots in an area of the image; and
(d) counting the bright spots identified in step (c), thereby providing an estimate of the amount of one or more analytes in the sample.
US Pat. No. 10,653,590

CONCENTRATED SHAMPOO DOSAGE OF FOAM FOR PROVIDING HAIR CARE BENEFITS COMPRISING AN ANIONIC/ZWITTERIONIC SURFACTANT MIXTURE

The Procter and Gamble Co...

1. A dosage of foam shampoo comprising a volume of from about 5 cm3 to about 150 cm3 of the foam, wherein the foam comprises:a) a detersive surfactant system comprising:i) from about 15 wt. % to about 30 wt. % anionic surfactant selected from the group consisting of sodium undecyl sulfate, sodium laureth sulfate, sodium lauroyl isethionate, sodium cocoyl isethionate, sodium laurethsulfosuccinate, sodium laurylsulfosuccinate, and mixtures thereof;ii) from about 2 wt. % to about 12 wt. % zwitterionic surfactant selected from the group consisting of lauramidopropyl betaine, cocoamidopropyl betaine, lauryl hydroxysultaine, and mixtures thereof;b) from about 0.0035 g to about 0.7 g of a particulate selected from the group consisting of zinc pyrithione, zinc carbonate, ethylene glycol distearate, mica, titanium dioxide, and combinations thereof; and
c) from about 45 wt. % to about 78 wt. % water; wherein:
1) the foam has a foam density of from about 0.04 g/cm3 to about 0.23 g/cm3; and
2) the foam has a plurality of bubbles comprising a bubble size distribution having a Sauter mean radius R32 of from about 10 ?m to about 60 ?m as measured according to the Kruss Lather Analyzer Method.
US Pat. No. 10,655,126

METHODS AND COMPOSITIONS TO TREAT DRUG-INDUCED DISEASES AND CONDITIONS

University of Vermont and...

1. A method for treating an acetaminophen-induced liver disease or condition in a subject, the method comprising administering to a subject in need of such treatment an MCJ-inhibiting compound in an amount effective to treat the acetaminophen-induced liver disease or condition in the subject, wherein the MCJ-inhibiting compound reduces MCJ polypeptide activity in the subject and decreasing the MCJ polypeptide activity comprises decreasing one or more of an MCJ polypeptide level or activity, and wherein the MCJ-inhibiting compound comprises am MCJ small interference RNA molecule (MCJ siRNA) or an MCJ small hairpin RNA molecule (MCJ shRNA).
US Pat. No. 10,653,591

LIQUID OIL-DISPERSIBLE TYPE EYE MAKEUP COMPOSITION

AMOREPACIFIC CORPORATION,...

1. A liquid oil-dispersible type eye makeup composition comprising:a volatile oil; a hard type film forming agent; and a soft type film forming agent,
wherein the volatile oil is a volatile hydrocarbon oil, a volatile silicone oil, or a mixture thereof,
wherein the hard type film forming agent is a silicone-based film forming agent comprising MQ resin, wherein
M resin is represented by R3SiO1/2;
Q resin is represented by SiO2;
R is an alkyl group having 1 to 8 carbon atoms or an aryl group having 5 to 15 carbon atoms; and
said MQ resin has an M/Q ratio of 0.7 to 0.8; and
wherein the soft type film forming agent is a silicone graft acrylic polymer-based film forming agent; and
wherein the hard type film forming agent and the soft type film forming agent are mixed at a weight ratio of from 60:40 to 30:70.
US Pat. No. 10,654,872

POLYMORPHS OF DOLUTEGRAVIR AND SALTS THEREOF

Laurus Labs Limited, Hyd...

1. Dolutegravir 1-amino-2-propanol solvate.
US Pat. No. 10,655,128

COMPOSITIONS AND METHODS FOR MODULATING MECP2 EXPRESSION

Translate Bio MA, Inc., ...

1. A single stranded oligonucleotide produced by a process comprising:synthesizing a single stranded oligonucleotide that:
(a) has a sequence 5?-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 3-23 nucleotides in length,
(b) is complementary with at least 10 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, wherein the PRC2-associated region is a region of the MECP2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the MECP2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and and
wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue.
US Pat. No. 10,656,152

POSTERIOR SEGMENT DRUG DELIVERY

ForSight Vision4, Inc., ...

1. A therapeutic device to treat an eye of a patient, the eye having a posterior segment and a sclera, the therapeutic device comprising:a rigid-walled, refillable reservoir having a volume, the reservoir adapted to reside in the posterior segment when the device is implanted in the eye;
a rigid, porous structure located at a distal region of the reservoir comprising sintered material;
a proximal cap portion positioned proximal of the reservoir and adapted to be positioned outside the sclera when the device is implanted in the eye, the cap portion comprising a retention structure and a penetrable, non-permeable barrier to introduce the therapeutic agent into the device without any need to explant the device during introduction of the therapeutic agent into the device; and
a neck portion positioned between the cap portion and the reservoir portion and defined by a cross-sectional shape that is smaller than a cross-sectional shape of the reservoir and a cross-sectional shape of the cap portion,
wherein the cross-sectional shape of the neck portion is non-circular and the cross-sectional shape of the reservoir is circular, and the sclera is positioned about the neck portion when the device is positioned in the eye.
US Pat. No. 10,653,593

SHELL-STRUCTURED PARTICLES FOR SUNSCREEN APPLICATIONS

International Business Ma...

1. A method, comprising:selecting one or more particles to serve as a coating layer in a sunscreen composition, wherein the one or more selected particles comprise one or more indium oxy-sulfide particles; and
coating one or more zinc oxide particles with the one or more selected particles.
US Pat. No. 10,655,129

COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN

IONIS PHARMACEUTICALS, In...

1. An antisense oligonucleotide 12 to 35 nucleotides in length comprising at least 12 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs:wherein the antisense oligonucleotide has at least one modified internucleoside linkage, sugar moiety, or nucleobase.
US Pat. No. 10,656,153

DIAGNOSTIC METHOD AND DEVICES FOR AUTOIMMUNE DISEASE

PZM DIAGNOSTICS, LLC, Ch...

1. A diagnostic device comprising:a first surface area having a first bacterial protein homologous to a first human protein bound thereto;
a second surface area having a second bacterial protein homologous to a second human protein bound thereto and
a solution comprising labeled antibodies against antibodies to the first bacterial protein and antibodies to the second bacterial protein,
wherein the second bacterial protein is different from the first bacterial protein and wherein the first bacterial protein and the second bacterial protein are selected from the group consisting of RNA polymerase B (PROB), elongation factor G (EF-G), heat shock protein 65 (hsp65), ATP synthase alpha (ATP5a), and elongation factor Tu (EF-Tu).
US Pat. No. 10,653,082

MAIZE INBRED PH4D3C

PIONEER HI-BRED INTERNATO...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH4D3C, representative seed of the variety having been deposited under ATCC accession number PTA-126377.
US Pat. No. 10,653,594

METHODS AND KITS OF REMOVING CALCULUS

3M INNOVATIVE PROPERTIES ...

1. A method of removing calculus from a tooth comprising:applying a component A to the tooth surface, wherein the component A comprises at least 0.1 wt-% hydrogen peroxide or a precursor thereto providing at least 0.1 wt-% hydrogen peroxide;
applying a component B to the tooth surface, thereby generating oxygen, wherein the component B comprises at least 30 units/mL catalase; and
removing at least a part of the calculus from the tooth surface;
wherein the component A is applied to the tooth surface before or after the component B is applied to the tooth surface;
wherein after the component B is applied to the tooth surface, the concentration of catalase inside the oral cavity increases above the natural concentration of catalase present inside the oral cavity prior to the application of the component B.
US Pat. No. 10,654,874

HETEROCYCLIC COMPOUND AND USE THEREOF

Takeda Pharmaceutical Com...

1. A method for the treatment of cognitive impairment associated with schizophrenia, comprising administering an effective amount of 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide or a salt thereof to a mammal.
US Pat. No. 10,655,130

MODULATION OF BREAST CANCER GROWTH BY MODULATION OF XBP1 ACTIVITY

Cornell University, Itha...

1. A method for treating triple negative breast cancer (TNBC) in a subject, the method comprising administering to the subject a direct inhibitor of X-box binding protein 1 (XBP1) and doxorubicin each in an amount effective to inhibit growth of cancer cells in said subject, such that TNBC in the subject is treated;wherein the direct inhibitor of XBP1 is an XBP1 shRNA.
US Pat. No. 10,656,154

METHODS FOR DETECTING AN AMOUNT OF COMPLEMENT FACTOR B PROTEIN AND CARBOHYDRATE ANTIGEN 19-9 PROTEIN, AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER USING THE SAME

JW HOLDINGS CORPORATION, ...

1. A method for diagnosing and treating pancreatic cancer in a subject, the method comprising the steps of:(a) collecting a blood sample from the subject;
(b) detecting an amount of human complement factor B (CFB) protein and an amount of human carbohydrate antigen 19-9 (CA 19-9) in the blood sample of the subject respectively;
(c) comparing the amount of CFB protein and the amount of CA19-9 detected in said step (b) to a reference amount of CFB protein and a reference amount of CA 19-9, respectively;
(d) diagnosing the subject with pancreatic cancer and determining an absence of at least one disease or condition selected from the group consisting of pancreatitis, liver cancer, bile duct cancer, and stomach cancer when both the amount of CFB protein and the amount of CA 19-9 in the blood sample detected in said step (c) are greater than the respective reference amounts; and
(e) treating the diagnosed subject by at least one of (i) administering an effective amount of a therapeutic agent for pancreatic cancer to the diagnosed subject, (ii) conducting a curative surgery, and (iii) conducting a radiation therapy,
wherein the reference amounts are an amount of CFB protein and an amount of CA 19-9 in a blood sample from a subject not having pancreatic cancer, and
wherein the CFB protein consists of the amino acid sequence of SEQ ID NO: 1.
US Pat. No. 10,653,083

MAIZE INBRED PH42M1

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42M1, representative seed of the variety having been deposited under ATCC accession number PTA-126661.
US Pat. No. 10,653,595

TOOTH WHITENING ORAL CARE COMPOSITION

Colgate-Palmolive Company...

1. An oral care system comprising(a) a first non-aqueous composition comprising:
(i) a peroxide-containing whitening agent; and
(ii) at least one silicone polymer,
and
(b) a second composition consisting essentially of:
(i) 2-propenoic acid, 2-methyl-2-methylpropyl ester, polymer with 2-propenoic acid and N-(1,1,3,3-tetramethylbutyl)-2-propenamide); and
(ii) a solvent, wherein the solvent is ethanol;
wherein the first composition and the second composition are maintained separately from one another.
US Pat. No. 10,655,131

APTAMER SPECIFICALLY BINDING TO L-ASCORBIC ACID AND USE OF THE SAME

NEXMOX Co., Ltd., Yongin...

1. A single-stranded DNA aptamer which inhibits oxidation by binding to L-ascorbic acid,the single stranded DNA aptamer having at least one
from 5? to 3? end direction CG-N1-XG step-loop structure,
wherein C is prior to an unpaired loop sequence G-N1-X in which N1 is any of 1 to 3 nucleotides and X is G or T, and G is subsequent to the unpaired loop sequence and forms a C-G bond with the C.
US Pat. No. 10,653,596

WHITE CHARCOAL TOOTHPASTE COMPOSITION AND METHOD

TOTAL CLEAN HOLDINGS LLC,...

1. A method for preparing a white activated charcoal, comprising: subjecting a charcoal ingredient to an incineration step and a bleaching step.
US Pat. No. 10,655,132

METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF

THE FLORIDA INTERNATIONAL...

1. An electrochemical aptamer-based (E-AB) sensor comprising a structure-switching cross-reactive aptamer and an electrode, the structure-switching cross-reactive aptamer being conjugated to the surface of the electrode, the structure-switching cross-reactive aptamer comprising SEQ ID No: 19.
US Pat. No. 10,656,156

DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IGG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E

Mepur Ravindranath, Los ...

1. An antibody comprising the heavy chain and light chain complementarity determining regions of the antibody that is produced by the hybridoma that is deposited at American Type Culture Collection Patent Deposit Number PTA-125908.
US Pat. No. 10,653,085

HEMP PLANT NAMED ‘CW1AS1’

1. A seed, plant, plant part, or plant cell of a hemp plant variety designated ‘CW1AS1’, wherein representative seed of the variety has been deposited under NCIMB No. 43291.
US Pat. No. 10,653,597

ANTIMICROBIAL COMPOSITION COMPRISING THYMOL, TERPINEOL AND A CATIONIC PHOSPHOLIPID

CONOPCO, INC., Englewood...

1. An antimicrobial composition comprising;a) 0.01 to 2% by weight of thymol;
b) 0.01 to 2% by weight of terpineol; and
c) 0.1 to 2% by weight of a cationic phospholipid complexwherein the cationic phospholipid complex is linoleamidopropyl PG-dimonium chloride phosphate.
US Pat. No. 10,655,133

METHOD FOR PREPARING DNA UNIT COMPOSITION, AND METHOD FOR CREATING CONCATENATED DNA

SYNPLOGEN CO., LTD., Hyo...

1. A method of preparing a DNA unit fragment composition, comprising:a step of preparing solutions containing multiple kinds of DNA unit fragments, each solution containing one of the multiple kinds of DNA unit fragments, each DNA unit fragment being attached to a corresponding auxiliary sequence; and
a step of, after preparing each solution, measuring the concentration of each kind of DNA unit fragment with the corresponding auxiliary sequence attached thereto in each of the solutions, and then based on the measurement result, taking a portion from each of the solutions so that the number of moles of DNA unit fragment in one portion is the same as the number of moles of DNA unit fragment in another portion, and combining each of the portions to prepare the DNA unit fragment composition.
US Pat. No. 10,653,086

BARLEY CULTIVAR BG KATANA

Highland Specialty Grains...

1. A plant of barley cultivar BG Katana, wherein a sample of seed of the barley cultivar BG Katana has been deposited under ATCC Accession No. PTA-126598.
US Pat. No. 10,653,598

DECOLORING OF DYED KERATIN FIBERS

1. A multi-component packaging unit (kit of parts) for reductively decoloring dyed keratin fibers, which includes(I) a container (A) containing a cosmetic agent (a) comprising a reductant of formamidine sulfinic acid and/or physiologically acceptable salts thereof,
(II) a container (B) containing a cosmetic agent (b) comprising water and monoethanolamine, wherein agent (b) has a pH of 7 to 12,
(III) a container (C) containing an aqueous, cosmetic agent (c) comprising 1.0 to 5.0 wt % maleic acid and 1.0 to 5.0 wt % citric acid,
wherein agent (c) has a pH of 0.5 to 4.0.
US Pat. No. 10,656,158

IDENTIFICATION OF ENZYME ACTIVITY THROUGH DETERMINATION OF ITS LOCALIZATION

INTERNATIONAL BUSINESS MA...

1. A method for analyzing enzyme activity within a cell, the method comprising:attaching a fluorescent reporter to an enzyme within the cell to form a tagged enzyme, the enzyme being a part of a metabolic pathway;
contacting the cell with a molecule that affects localization of the tagged enzyme within the cell, wherein the molecule is selected from the group consisting of fosfomycin, insulin, EGF, glucose, and 1-methionine and combinations thereof;
assaying by fluorescence imaging the tagged enzyme within the cell to determine whether the tagged enzyme is localized or diffuse within the cell;
wherein, based on whether the tagged enzyme is localized or diffuse within the cell, determining whether the molecule promotes or disrupts localization of the tagged enzyme, respectively; and
wherein, based on whether the tagged enzyme is localized or diffuse within the cell, determining whether the tagged enzyme is metabolically active or inactive, respectively.
US Pat. No. 10,653,087

WHEAT CULTIVAR 01071495

Monsanto Technology LLC, ...

1. A plant of wheat cultivar 01071495, wherein a representative sample of seed of said cultivar has been deposited under ATCC Accession No. PTA-126326.
US Pat. No. 10,653,599

HAIR TREATMENT AGENT WITH A POLYVALENT CATION II

1. A hair treatment agent for strengthening the internal hair structure with a pH in a range of from about 3.5 to about 5 comprising relative to the total quantity of hair treatment agent—a) from about 0.01 to about 10 wt. % of a polyvalent metal salt, wherein the metal salt is selected from the group of lanthanum maleate and lanthanum chloride in combination with aluminum lactate; and
b) from about 0.01 to about 10 wt. % of an organic acid selected from the group of maleic acid, lactic acid, and mixtures thereof.
US Pat. No. 10,655,135

ORALLY ADMINISTERED PLASTID EXPRESSED CHOLERA TOXIN B SUBUNIT-EXENDIN 4 AS TREATMENT FOR TYPE 2 DIABETES

The Trustees of the Unive...

1. A plant plastid comprising a plastid genome transformed with a heterologous expression cassette consisting of, as operably linked components in the 5? to the 3? direction of translation, a flanking sequence having homology to a trnl region in the plastid genome, a Prrn promoter operative in said plastid, an aadA selectable marker sequence or an antibiotic free selectable marker sequence, a psbA 5? untranslated region sequence, a cholera toxin B subunit(CTB)-Exendin fusion gene sequence, a psbA 3? untranslated region sequence, and a flanking sequence having homology to a trnA region in the plastid genome, said expression cassette being integrated into said plastid genome such that said CTB-Exendin is expressed in and present in said plastid, wherein the CTB-Exendin 4 fusion protein has a hinge region, and a furin cleavage site between the CTB and the Exendin 4, and wherein the hinge-furin cleavage site-exendin portion consists of SEQ ID NO: 7, said plastid being suitable for oral administration of said CTB-Exendin 4 to a subject in need thereof.
US Pat. No. 10,656,159

IMMUNOASSAYS OF S-ADENOSYLMETHIONINE AND METHYLATION INDEX IN PERSONALIZED MEDICINE AND HEALTH EVALUATION

HUNAN SKYWORLD BIOTECHNOL...

1. A method for screening, diagnosing and monitoring a disease or condition in a subject comprising the steps of: (a) obtaining a biological sample from a patient to be screened, diagnosed or monitored; (b) determining using an immunoassay the quantity of SAM and SAH in said biological sample; (c) calculating the methylation index of said biological sample; (d) comparing said methylation index of step (c) to the patient's baseline reference methylation index profile; and (e) determining if the quantity(ies) of said SAM, SAH and methylation index in said biological sample is(are) indicative of the presence, absence or stages of any diseases or conditions; and wherein said immunoassay in step (b) utilizes a monoclonal antibody derived from hybridomas having the designation from the China Center For Type Culture Collection (CCTCC) number C2017178 and number C2017179.
US Pat. No. 10,653,088

VARIETY CORN LINE KFX7404

Syngenta Crop Protection ...

1. A seed of maize variety KFX7404, wherein representative seed of said maize variety KFX7404 has been deposited under ATCC Accession Number PTA-125503.
US Pat. No. 10,655,136

METHODS AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS INTO PLANTS

MONSANTO TECHNOLOGY LLC, ...

1. A method for silencing a target gene in a plant, comprising, in any order, the steps of:(a) abrading a surface of a plant with a particulate of a size greater than about 2.5 micrometers;
(b) applying an RNA to the surface of the plant, wherein the RNA comprises a sequence that is complementary or identical to 21 or more contiguous nucleotides in the sequence of a target gene in the plant;
wherein the particulate, the RNA, or both, are further applied with an osmolyte, and
whereby the target gene is silenced.
US Pat. No. 10,656,160

URINALYSIS DEVICE AND DRY REAGENT FOR QUANTITATIVE URINALYSIS

Nitto Denko Corporation, ...

1. A formulation for use in analysis of a concentration of creatinine in a sample, the formulation comprising:a strong base in a concentration of from about 40 to about 80 g/L;
a buffer in a concentration of from about 50 to about 250 g/L;
at least two surfactants in a concentration of from about 0.1 to about 20 g/L;
a compound that reacts with creatinine to generate a product; and
water;
wherein the at least two surfactants comprises an anionic surfactant in a concentration from about 0.1 to about 10 g/L and a cationic surfactant in a concentration from about 0.1 to about 10 g/L, and
wherein the cationic surfactant includes a quaternary ammonium moiety.
US Pat. No. 10,653,089

VARIETY CORN LINE KFX5365

Syngenta Crop Protection ...

1. A seed of maize variety KFX5365, wherein representative seed of said maize variety KFX5365 has been deposited under ATCC Accession Number PTA-125502.
US Pat. No. 10,653,601

WATER SOLUBLE SURFACTANT COMPOSITION HAVING IMPROVED TASTE

1. An oral care composition exhibiting improved taste comprising:a. from about 3% to about 20%, by weight of the composition, of water; and
b. a surfactant wherein the surfactant comprises cocoamidopropyl betaine, wherein the surfactant comprises less than 1%, by weight of the surfactant, of one or more undesirable materials selected from the group consisting of amines, amides, and combinations thereof; and from 0.01% to 3%, by weight of the surfactant, of a second undesirable material selected from the group consisting of dodecanal, methyl 6,8-dodecadienyl ether, dodecanol, ethylene glycol monodecyl ether, and combinations thereof.
US Pat. No. 10,654,881

NON-CALORIC SWEETENER

Conagen Inc., Bedford, M...

1. A method for synthesizing rebaudioside D, the method comprising:preparing a reaction mixture comprising rebaudioside A; a substrate selected from the group consisting of sucrose, uridine diphosphate (UDP) and uridine diphosphate-glucose (UDP-glucose); and a UDP-glycosyltransferase fusion enzyme comprising a uridine diphospho glycosyltransferase domain coupled to a sucrose synthase domain; wherein the uridine diphospho glycosyltransferase domain is an Oryza sativa uridine diphospho glycosyltransferase EUGT11 comprising the amino acid sequence of SEQ ID NO: 1, and the sucrose synthase domain is selected from the group consisting of an Arabidopsis sucrose synthase 1, a Coffea sucrose synthase 1, and a Stevia sucrose synthase 1, and incubating the reaction mixture for a sufficient time to produce rebaudioside D, wherein a glucose is covalently coupled to the rebaudioside A to produce rebaudioside D.
US Pat. No. 10,655,137

INFLUENZA MUCOSAL VACCINE COMPOSITION AND PREPARATION AND APPLICATION THEREOF

NATIONAL TSING HUA UNIVER...

1. An influenza mucosal vaccine composition, comprising an antigen fusion protein, wherein the antigen fusion protein comprises an influenza virus antigen and the Type IIb heat-labile enterotoxin A subunit from Escherichia coli.
US Pat. No. 10,653,090

VARIETY CORN LINE GAN1005

Syngenta Crop Protection ...

1. A seed of maize variety GAN1005, wherein representative seed of said maize variety GAN1005 has been deposited under ATCC Accession Number PTA-125496.
US Pat. No. 10,653,091

VARIETY CORN LINE IDI4138

Syngenta Crop Protection ...

1. A seed of maize variety IDI4138, wherein representative seed of said maize variety IDI4138 has been deposited under ATCC Accession Number PTA-125497.
US Pat. No. 10,655,139

NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR MODIFYING PLANT CHARACTERISTICS

CERES, INC., Thousand Oa...

1. A method for increasing water use efficiency in a plant comprising transforming a plant with a nucleic acid molecule, wherein the nucleic acid molecule comprises:a) a first nucleic acid having a regulatory sequence capable of causing transcription in a plant; and
b) a second nucleic acid encoding a polypeptide, wherein the polypeptide comprises an amino acid sequence that exhibits at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO:7;
wherein said first and second nucleic acids are operably linked,
wherein said second nucleic acid is heterologous to said first nucleic acid, and
wherein expression of said second nucleic acid in a plant increases water use efficiency as compared to a control plant of the same species lacking said nucleic acid molecule.
US Pat. No. 10,656,163

METHOD FOR DETERMINING RISK OF PRE-ECLAMPSIA

Wallac Oy, Turku (FI)

1. A method of treating a pregnant individual with chronic hypertension identified as at risk for developing superimposed early onset pre-eclampsia, the method consisting of the steps:(a) detecting chronic hypertension in a pregnant individual;
(b) collecting at least one blood sample from the individual within a first trimester;
(c) detecting levels of Placental growth factor (PlGF) and sP-selectin in the at least one blood sample; and
(d) identifying the pregnant individual as having an increased risk of superimposed early onset pre-eclampsia if both of the following occur: the detected level of PlGF in the at least one blood sample is decreased as compared to a level of PlGF in a control sample, and the detected level of sP-Selectin in the at least one blood sample is increased as compared to a level of sP-selectin in a control sample; and
(e) treating the identified pregnant individual with aspirin to lower the pregnant individual's risk of superimposed early onset pre-eclampsia.
US Pat. No. 10,653,092

VARIETY CORN LINE KFX5302

Syngenta Crop Protection ...

1. A seed of maize variety KFX5302, wherein representative seed of said maize variety KFX5302 has been deposited under ATCC Accession Number PTA-125921.
US Pat. No. 10,655,140

HERBICIDE-RESISTANT PROTEIN, ENCODING GENE AND USE THEREOF

BEIJING DABEINONG BIOTECH...

1. A herbicide-resistant protein, comprising a protein consisting of the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,653,093

MAIZE INBRED PH40SW

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH40SW, representative seed of the variety having been deposited under ATCC accession number PTA-126663.
US Pat. No. 10,653,605

DENTIFRICE COMPOSITION

GABA International Holdin...

1. A dentifrice comprising 0.4 to 0.6% chitosan or pharmaceutically acceptable acid addition salt thereof, 1300 to 1500 ppm fluoride ions and an abrasive, for use against erosive tooth demineralization, wherein the dentifrice is a toothpaste comprising a liquid phase and comprising 3500 ppm tin dissolved in the liquid phase;wherein the fluoride ions are a combination of amine fluoride and sodium fluoride,
wherein the chitosan or pharmaceutically acceptable acid addition salt thereof and the fluoride ions are dissolved in the liquid phase; and
the chitosan comprises unmodified chitosan.
US Pat. No. 10,655,141

PLANT EPSP SYNTHASES AND METHODS OF USE

PIONEER HI-BRED INTERNATI...

12. A method of generating a glyphosate tolerant plant, the method comprising: a) expressing in a regenerable plant cell a recombinant DNA construct comprising a polynucleotide operably linked to at least one heterologous regulatory sequence, wherein the polynucleotide encodes a plant EPSP synthase (EPSPS) polypeptide that comprises G102A and at least one amino acid mutation selected from the group consisting of:i. A2R, ii. A4W, iii. H54M, iv A72Q, v. K84R, vi. L98C, vii. K173R, viii, I208L, ix, K243E, x. T279A, xi. E302S, xii. T361S, xiii. E391P, xiv. E391G, xv. D402G, xvi. A416G, xvii. V438R, xviii. S440R, xix. T441Q, and xx. F442V; wherein each amino acid mutation position corresponds to the amino acid position set forth in SEQ ID NO:1 and wherein the plant EPSPS polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:2; and b) generating the glyphosate tolerant plant, wherein the glyphosate tolerant plant comprises in its genome the recombinant DNA construct.
US Pat. No. 10,653,094

MAIZE INBRED PH47HS

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH47HS, representative seed of the variety having been deposited under ATCC accession number PTA-126524.
US Pat. No. 10,653,606

AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS

2. A method for the temporary deformation of keratin-containing fibers, the method comprising applying the cosmetic composition according to claim 1 to the keratin-containing fibers.
US Pat. No. 10,655,142

MOLECULAR MARKERS LINKED TO DISEASE RESISTANCE IN SOYBEAN

Syngenta Participations A...

1. A method of producing a Glycine max plant that has improved resistance to Phytophthora sojae as compared to a control plant, the method comprising the steps of:(a) isolating a nucleic acid from a Glycine max plant;
(b) detecting in the nucleic acid of (a) the presence of a genetic marker that is associated with improved resistance to Phytophthora sojae and is associated with Rps1-k, wherein the genetic marker comprises SY2725AQ (SEQ ID NO: 8) and further comprises an A allele at nucleotide 251 of SEQ ID NO:8, or is a marker closely linked thereto on Soybean Chromosome 3, wherein the marker closely linked thereto comprises at least one of an A allele at nucleotide 251 of SEQ ID NO:6 (SY2724BQ) or an A allele at nucleotide 251 of SEQ ID NO:7 (SY2724CQ);
(c) selecting a first Glycine max plant based on the presence of the genetic marker detected in (b);
(d) crossing a second Glycine max plant with the first Glycine max plant of (c) wherein, said second Glycine max plant does not comprise in its genome the genetic marker detected in (b); and
(e) producing seed from the crossing of (d) and thereby producing a Glycine max plant that has improved resistance to Phytophthora sojae as compared to a control plant.
US Pat. No. 10,655,654

USE OF TREATING ELEMENTS TO FACILITATE FLOW IN VESSELS

CRYSTAPHASE PRODUCTS, INC...

1. A method of improving flow distribution of one or more streams in a process vessel comprising:passing the one or more streams through an upstream processing zone and a downstream processing zone within the process vessel, the upstream processing zone and downstream processing zone each containing one or more beds of processing materials;
passing the one or more streams through a redistribution treating zone located between the upstream processing zone and downstream processing zone, wherein the redistribution treating zone comprises at least one layer of a fixed, form-fit fibrous mesh material conforming to the interior dimensions of the process vessel; and
laterally dispersing the one or streams with the fibrous mesh material to provide improved contact between the one or more streams and the processing materials in the downstream processing zone.
US Pat. No. 10,656,166

INHIBITING CHRONIC BLOOD AND NEPHROLOGICAL DISORDERS USING LYSINE-BASED SUPPLEMENTS

Lysulin, Inc., San Diego...

1. A method of monitoring blood glucose levels, the method comprising:measuring a current blood glucose level of an individual from a biochemistry test;
determining the current blood glucose level; and
administering a supplement to the individual consisting of lysine, zinc, and vitamin C.
US Pat. No. 10,653,095

MAIZE INBRED PH487D

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH487D, representative seed of the variety having been deposited under ATCC accession number PTA-126657.
US Pat. No. 10,653,607

AGENT AND METHOD FOR THE TEMPORARY DEFORMATION OF KERATIN-CONTAINING FIBERS

2. A method for the temporary shaping of keratin-containing fibers, the method comprising exposing keratin fibers to a cosmetic composition according to claim 1.
US Pat. No. 10,654,887

SEPARATION MATRIX


wherein individually of each other:
X1=A, Q, or is deleted
X2=E, K, Y, T, F, L, W, I, M, V, A, H or R
X3=H or K
X4=A or N
X5=A, G, S, Y, Q, T, N, F, L, W, I, M, V, D, E, H, R or K
X6=Q or E
X7=S or K
X8=E or D
X9=Q, V, or is deleted
X10=K, R, A, or is deleted
X11=A, E, N, or is deleted
X12=I or L
X13=K or R
X14=L or Y
X15=D, F, Y, W, K or R.
US Pat. No. 10,655,143

INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE

PIONEER HI-BRED INTERNATI...

1. A recombinant nucleic acid molecule encoding a Pseudomonas Insecticidal Protein-1 (PIP-1) polypeptide having at least 95% identity to the full-length amino acid sequence of SEQ ID NO: 2 and having oral insecticidal activity against an insect pest in the order Hemiptera and/or an insect pest in the order Lepidoptera, wherein the recombinant nucleic acid is operably linked to a heterologous regulatory element.
US Pat. No. 10,656,167

ASSAYS TO MONITOR BLEEDING DISORDERS

BIOVERATIV THERAPEUTICS I...

1. A method of treating a hemophilia A in a human subject wherein the subject is administered with a Factor VIII (FVIII) chimeric polypeptide, the method comprisingmeasuring the subject's thrombin generation activity using a thrombin generation assay (TGA) in a blood sample from the human subject, wherein the assay is performed in the presence of an exogenous thrombin at a concentration of about 5 nM, but in the absence of exogenous tissue factor;
comparing the subject's thrombin generation activity with a corresponding standard, wherein the standard correlates with a therapeutically efficacious treatment;
determining an optimized dose or dosing interval of the FVIII chimeric polypeptide based on the relative difference between the subject's thrombin generation activity and the corresponding standard; and
administering the FVIII chimeric polypeptide to the subject at the determined optimized dose or dosing interval during subsequent administrations,wherein the FVIII chimeric polypeptide comprises a FVIII and an FcRn binding partner, and wherein the FcRn binding partner comprises an Fc region or albumin.
US Pat. No. 10,653,096

MAIZE INBRED PH41MH

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41MH, representative seed of the variety having been deposited under ATCC accession number PTA-126375.
US Pat. No. 10,653,608

AGENTS AND METHODS FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS

1. A cosmetic product comprising:a) a cosmetic preparation comprising, with respect to its total weight;
a1) about 45% to about 98% by weight of at least one polar solvent; and
a2) about 0.5% to about 15% by weight of at least one copolymer comprising the monomers:
i) N-tert-octylacrylamide,
ii) acrylic acid, and
iii) tert-butylaminoethylmethacrylate; and
b) a device for flash evaporation of the cosmetic preparation a), wherein the device for flash evaporation comprises:
b1) a delivery container defining an interior in which the cosmetic preparation can be received;
b2) a valve configured to selectively close and open the interior of the delivery container;
b3) a heating apparatus for heating, under increased pressure, the cosmetic preparation in the interior of the delivery container when closed, and for releasing, under reduced pressure, the cosmetic preparation after heating from the interior of the delivery container into a surrounding environment;
b4) a nozzle configured to atomize the cosmetic preparation escaping from the delivery container; and
b5) an upstream storage container for the cosmetic preparation from which the cosmetic preparation can enter the delivery container through an access, wherein the pressure in the interior of the upstream storage container corresponds to the ambient pressure, wherein the upstream storage container has at least ten times the volume of the delivery container, and wherein the access between the upstream storage container and the delivery container includes a component for flow control configured to selectively interrupt flow of the cosmetic preparation from the upstream storage container into the delivery container.
US Pat. No. 10,654,888

METHOD FOR REMOVING VIRUSES IN A PHYSIOLOGICALLY-ACTIVE PROTEIN-CONTAINING SAMPLE

CHUGAI SEIYAKU KABUSHIKI ...

1. A method for removing viruses in a physiologically active protein-containing sample which comprises viruses, which comprises the steps of:1) applying the physiologically active protein-containing sample which comprises viruses to a protein chromatography column, and eluting, by means of applying an aqueous eluting solution to said column, an eluate comprises said viruses,
2) mixing the eluate of step (1) with an aqueous solution of low conductivity and
a pH equal to or lower than the isoelectric point of the physiologically active protein; and
3) removing resulting particles comprising viruses,
wherein the step 2) is accomplished by forming the physiologically active protein-containing sample comprising viruses into an acidic aqueous solution of low conductivity, and increasing the pH of the resulting sample to a pH equal to or less than the isolectric point of the physiologically active protein, and
wherein the acidic aqueous solution of low conductivity has a molarity of 0 to 100 mM.
US Pat. No. 10,655,144

NUCLEIC ACID CONSTRUCT WITH A P16 PROMOTER THAT CAUSES A PRODRUG CONVERTING ENZYME TO BE EXPRESSED SPECIFICALLY IN SENESCENT CELLS

Buck Institute for Resear...

1. A nucleic acid construct comprising a p16INK4a promoter sequence operably linked to a nucleic acid sequence encoding an enzyme such that the enzyme is expressed when the construct is present in senescent cells;wherein the enzyme has enzymatic activity that converts a particular prodrug to a cytotoxic agent;
wherein administering the prodrug to a tissue that contains senescent cells expressing the enzyme results in the prodrug being converted to the cytotoxic agent, thereby selectively killing the senescent cells but killing less than 10% of non-senescent cells in the same tissue;
whereby progression of an age-related disorder or an age-sensitive trait is delayed in the tissue compared with a tissue to which the prodrug is not administered.